Administration of STING agonists, checkpoint inhibitors, and radiation

JP2023550740A5Active Publication Date: 2024-11-26TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529980
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-04
Filing Date
2021-11-18
Publication Date
2024-11-26
Estimated Expiration
2041-11-18

AI Technical Summary

Technical Problem

Current cancer treatments, including surgery, radiation therapy, and chemotherapy, have limitations in efficacy and require new combinations of therapeutic agents to improve patient outcomes, especially for resistant cancers.

Method used

Administering a STING agonist in combination with checkpoint inhibitors and radiation to enhance immune responses and target cancer cells.

Benefits of technology

The combination therapy effectively suppresses cancer cell proliferation and enhances immune activation, offering potential synergistic benefits over individual treatments, particularly for resistant cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022107027000001
    Figure 2022107027000001
  • Figure 2022107027000002
    Figure 2022107027000002
Patent Text Reader

Abstract

The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in a patient in need thereof. The methods include administering to a patient in need thereof a STING (stimulator of interferon genes) agonist, such as Compound No. 14 defined herein or a pharmaceutically acceptable salt thereof, in combination with one or more checkpoint inhibitors and radiation. Medicaments for use in treating cancer are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present disclosure relates to methods of treating cancer. Specifically, the present disclosure provides methods for treating various cancers by administering a STING (stimulator of interferon genes) agonist in combination with one or more checkpoint inhibitors and radiation. [Background technology]

[0002] In 2012, there were an estimated 14 million diagnosed cases of cancer worldwide, resulting in approximately 8.2 million deaths. The global cancer burden is growing at an alarming pace. In 2030 alone, approximately 21.3 million new cancer cases and 13.1 million cancer deaths are expected, due solely to population growth and aging. Cancer is the second most common cause of death in the United States, surpassed only by heart disease, accounting for nearly one-quarter of all deaths. The National Cancer Institute estimates that approximately 14.5 million Americans with a history of cancer were alive in 2014. While some of these individuals were cancer-free, others may still have evidence of cancer and have been treated. While medical advances have improved cancer survival rates, new and more effective treatments are continually needed.

[0003] Cancer treatment has primarily relied on surgery, radiation therapy, cytotoxic chemotherapy, and their combinations. However, within the past decade, targeted cancer therapy has ushered in a new era in the field of oncology. Targeted cancer therapy is a drug designed to interfere with specific molecules necessary for tumor growth and progression, and can include small molecules and larger chemical entities such as monoclonal antibodies (mAbs).

[0004] STING is a transmembrane receptor localized in the ER that recognizes and binds to cyclic dinucleotides. Natural ligands recognized by STING include bacterial / protozoan-derived cyclic dinucleotides (CDNs) and 2',3'-cGAMP, synthesized upstream by cGAS (cyclic GMP-AMP synthase). See Trends in Immunology 35:88-93 (2014). One of the natural ligands, 2',3'-cGAMP, is degraded by the pyrophosphatase / phosphodiesterase ENPP1 (ecto-nucleotide pyrophosphatase / phosphodiesterase), while other CDNs are degraded by other phosphodiesterases. See Nat Chem Biol 10:1043-1048 (2014), Cell Res 25:539-550 (2015), and Biochemistry 55:837-849 (2016). STING activation by these natural ligands induces phosphorylation of TBK1 (TANK-binding kinase 1) and IRF3 (interferon regulatory factor 3), leading to activation of NFkB and type I interferon (IFN) responses, respectively. See Trends in Immunology 35:88-93 (2014).

[0005] The effect of STING on cancer cell growth control has been demonstrated using genetically engineered mice. It has been reported that STING-deficient and IRF3-deficient mice exhibit uncontrolled tumor growth compared to wild-type mice. (See Immunity 41:830-842 (2014)). Additionally, it has been reported that cancer cell growth in tumor-allografted mice was suppressed by radiation therapy, but the efficacy of radiation therapy was reduced in mice genetically deficient in STING and IFNAR1 (interferon (alpha and beta) receptor 1, a receptor for type I IFN produced by downstream signaling). (See Immunity 41:843-852 (2014)). Collectively, the above evidence suggests that STING plays an important role in suppressing cancer cell growth. Therefore, STING can be used as an anticancer drug. Additionally, STING activation can further enhance the immune effects of conventional vaccines due to its ability to activate both innate and adaptive immunity. See Ther Adv Vaccines 1:131-143 (2013). Thus, STING agonists can also be used as adjuvants for various vaccines.

[0006] In addition to small molecules, targeted therapies include monoclonal antibodies. For example, among the many known monoclonal antibody targeted therapies are monoclonal antibodies against PD-1 (e.g., nivolumab / Opdivo® and pembrolizumab / Keytruda®), monoclonal antibodies against PD-L1 (e.g., atezolizumab / Tecentriq®, durvalumab / Imfinzi®, and avelumab / Bavencio®), and monoclonal antibodies against CTLA-4 (e.g., ipilimumab / Yervoy®). Thus, some cancers may be PD-1-mediated disorders, PD-L1-mediated disorders, and CTLA-4-mediated disorders. Additional monoclonal antibody targeted therapies include, but are not limited to, monoclonal antibodies against CD20 (e.g., rituximab / Rituxan®), CD52 (e.g., alemtuzumab / Campath®), VEGF (e.g., bevacizumab / Avastin®), HER2 (e.g., trastuzumab / Herceptin® for treating Her2+ breast and gastric cancer), and EGFR (e.g., cetuximab / Erbitux® for treating colorectal cancer).

[0007] Other therapies may include radiation or radiotherapy. Radiation therapy is a mainstay of cancer treatment, with approximately 50% of cancer patients receiving radiation therapy at some point during their disease course. Cancer, 104(6):1129-37 (2005). In the setting of metastatic disease from solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and squamous cell carcinoma of the head and neck (SCCHN), radiation therapy is often used for palliative purposes. Technological advances have made it possible to deliver radiation therapy more precisely using techniques such as three-dimensional conformal radiation therapy, image-guided intensity-modulated radiation therapy, and stereotactic ablative body radiotherapy (SAbR). BMJ, 345:e7765 (2012).

[0008] In order to extend the lifespan of patients while maintaining a high quality of life, new combinations of therapeutic agents that produce beneficial effects in cancer treatment are desirable. New combinations can provide increased benefits compared with each drug alone. In particular, combination treatment regimens can be useful for patients suffering from disease conditions, including proliferative disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases, and kidney diseases, and may also reduce the recurrence rate or overcome the resistance to certain anticancer drugs that is sometimes seen in these patients. This is especially true when cancer may be resistant or resistant to currently available treatment regimens.

[0009] Therefore, new treatment regimens, including combination therapies, are needed. Summary of the Invention

[0010] In one aspect, the present disclosure relates to a method of treating cancer, comprising administering to a subject in need of such treatment a STING agonist in combination with radiation.

[0011] In one aspect, the present disclosure relates to a method of treating cancer, comprising administering to a subject in need of such treatment a combination of a STING agonist, a checkpoint inhibitor, and radiation.

[0012] In one aspect, the present disclosure provides a method of treating a cancer patient, comprising administering to a patient in need thereof Compound No. 14, having the structure:

[0013] [ka]

[0014] or a pharmaceutically acceptable salt thereof and radiation.

[0015] In one aspect, the present disclosure provides a method of treating a cancer patient, comprising administering to a patient in need thereof Compound No. 14, having the structure:

[0016] [ka]

[0017] or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, and radiation.

[0018] In another aspect, the disclosure relates to a method of treating a cancer patient, comprising administering Compound No. 14 and a checkpoint inhibitor to a patient who has undergone radiation therapy. In some embodiments, Compound No. 14 and a checkpoint inhibitor are administered to the patient between 1 day and 3 months after the patient has been treated with radiation.

[0019] The following embodiments refer to both aspects of the invention.

[0020] In some embodiments, the checkpoint inhibitor is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

[0021] In some embodiments, the checkpoint inhibitor is an anti-PD-1 antibody.

[0022] In some embodiments, the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, lambrolizumab, pidilizumab, BMS-936559, and AMP-224.

[0023] In some embodiments, the checkpoint inhibitor is an anti-PD-L1 antibody.

[0024] In some embodiments, the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, durvalumab, avelumab, YW243.55.S70, MEDI-4736, MSB-0010718C, LY3300054, BMS-936559, MPDL3280A, and MDX-1105.

[0025] In some embodiments, the checkpoint inhibitor is an anti-CTLA-4 antibody.

[0026] In some embodiments, the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab.

[0027] In some embodiments, the radiation is particle radiation.

[0028] In some embodiments, the radiation is administered by external beam radiation.

[0029] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered orally.

[0030] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered intravenously.

[0031] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered by intravenous infusion.

[0032] In some embodiments, the checkpoint inhibitor is administered intravenously.

[0033] In some embodiments, the checkpoint inhibitor is administered by intravenous infusion.

[0034] In some embodiments, the checkpoint inhibitor is administered by subcutaneous injection.

[0035] In some embodiments, the checkpoint inhibitor is administered subcutaneously.

[0036] In some embodiments, Compound No. 14 and the checkpoint inhibitor are administered simultaneously.

[0037] In some embodiments, Compound No. 14 and the checkpoint inhibitor are administered sequentially in separate pharmaceutical compositions.

[0038] In some embodiments, the radiation, Compound No. 14, and checkpoint inhibitor are administered sequentially.

[0039] In some embodiments, radiation is administered prior to Compound No. 14 and the checkpoint inhibitor.

[0040] In some embodiments, the cancer is a PD-1 positive cancer, a PD-L1 positive cancer, or a CTLA-4 positive cancer.

[0041] In some embodiments, the cancer is a solid tumor or a hematological malignancy. In some embodiments, the cancer is a metastatic solid tumor. In some embodiments, the cancer is an advanced solid tumor.

[0042] In some embodiments, the cancer is melanoma, lung cancer, renal cancer, lymphoma, head and neck cancer, urothelial cancer, prostate cancer, bladder cancer, breast cancer, gastric cancer, colorectal cancer, leukemia, cervical cancer, microsatellite instability-high cancer, hepatocellular carcinoma, or Merkel cell carcinoma.

[0043] In some embodiments, the melanoma is metastatic melanoma, unresectable melanoma, or cutaneous melanoma.

[0044] In some embodiments, the lung cancer is non-small cell lung cancer or small cell lung cancer.

[0045] In some embodiments, the non-small cell lung cancer is metastatic non-small cell lung cancer, metastatic squamous non-small cell lung cancer, or metastatic non-squamous non-small cell lung cancer.

[0046] In some embodiments, the renal cancer is renal cell carcinoma.

[0047] In some embodiments, the lymphoma is classical Hodgkin's lymphoma or primary mediastinal large B-cell lymphoma.

[0048] In some embodiments, the head and neck cancer is head and neck squamous cell carcinoma.

[0049] In some embodiments, the urothelial cancer is urothelial carcinoma.

[0050] In some embodiments, the prostate cancer is hormone-refractory prostate cancer.

[0051] In some embodiments, the gastric cancer is gastroesophageal junction adenocarcinoma.

[0052] In some embodiments, the cancer is a microsatellite instability-high cancer.

[0053] In some embodiments, the cancer is triple-negative breast cancer.

[0054] In some embodiments, the cancer is a metastatic solid tumor.

[0055] In some embodiments, the checkpoint inhibitor is administered once every 12 weeks, once every 4 weeks, once every 3 weeks, once every 2 weeks, once a week, twice a week, three times a week, or daily.

[0056] In some embodiments, the checkpoint inhibitor is administered once every two weeks.

[0057] In some embodiments, the checkpoint inhibitor is administered once every three weeks.

[0058] In some embodiments, the checkpoint inhibitor is administered once every four weeks.

[0059] In some embodiments, the checkpoint inhibitor is administered once every 12 weeks.

[0060] In some embodiments, the checkpoint inhibitor is administered on day 1 or day 2 of the treatment cycle.

[0061] In some embodiments, the checkpoint inhibitor is administered on day 1 of the treatment cycle.

[0062] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once every two weeks, once a week, twice a week, three times a week, or daily.

[0063] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered twice a week.

[0064] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once a week.

[0065] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1, 8, and 15 of a treatment cycle.

[0066] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1, 4, 8, and 11 of a treatment cycle.

[0067] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1 and 8 of the treatment cycle.

[0068] The following embodiments relate to aspects of the invention in which radiation is administered.

[0069] In some embodiments, the radiation is administered between day −8 and day −1 of the treatment cycle.

[0070] In some embodiments, the radiation is administered between day −7 and day −1 of the treatment cycle.

[0071] In some embodiments, the radiation is administered on day 1 of the treatment cycle.

[0072] In some embodiments, the treatment cycle is 14 days, 21 days, 28 days, or 84 days.

[0073] In some embodiments, the treatment cycle is 21 days.

[0074] In some embodiments, compound no. 14 is administered on days 1, 8, and 15 of a treatment cycle, and a checkpoint inhibitor is administered on day 1 of the treatment cycle.

[0075] In some embodiments, compound number 14 is administered on days 1, 8, and 15 of the treatment cycle, the checkpoint inhibitor is administered on day 1 of the treatment cycle, and radiation is administered between days −8 and −1 of the treatment cycle.

[0076] In some embodiments, compound number 14 is administered on days 1, 8, and 15 of the treatment cycle, the checkpoint inhibitor is administered on day 1 of the treatment cycle, and radiation is administered between days −7 and −1 of the treatment cycle.

[0077] In some embodiments, compound number 14 is administered on days 1, 8, and 15 of the treatment cycle, the checkpoint inhibitor is administered on day 1 of the treatment cycle, and the radiation is administered at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14.

[0078] In some embodiments, the radiation is administered at least 40 hours prior to administration of the checkpoint inhibitor or Compound No. 14.

[0079] In some embodiments, radiation is administered in fractionated doses of about 5 Gy to about 20 Gy, or about 6 Gy to about 18 Gy, or about 8 Gy to about 16 Gy.

[0080] In some embodiments, radiation is administered in fractionated doses of about 5 Gy to about 10 Gy, or about 15 Gy to about 20 Gy.

[0081] In some embodiments, radiation is administered in fractionated doses of about 8 Gy or about 16 Gy.

[0082] In some embodiments, radiation is administered in 1 fraction, or 2 fractions, or 3 fractions, or 4 fractions, or 5 fractions.

[0083] In some embodiments, radiation is administered in one or three fractions.

[0084] In some embodiments, radiation is administered in one fraction at a fractional dose of about 8 Gy, or three fractions at a fractional dose of about 8 Gy, or one fraction at a fractional dose of about 16 Gy.

[0085] In some embodiments, the checkpoint inhibitor is administered in an amount of 200 mg, Compound No. 14 is administered in an amount of 0.05 mg to 2.5 mg, or in an amount of 0.2 mg to 1.2 mg, and the radiation is administered in a fractionated dose of about 8 Gy in 1 fraction, or in 3 fractionated doses of about 8 Gy, or in 1 fractionated dose of about 16 Gy.

[0086] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once every two weeks, once a week, twice a week, three times a week, daily, on days 1, 4, 8, and 11 of a 21-day cycle, or on days 1, 8, and 15 of a 21-day cycle; the checkpoint inhibitor is administered separately once every 12 weeks, once every four weeks, once every three weeks, once every two weeks, once a week, twice a week, three times a week, or daily; and the radiation is administered between days −8 and −1 of a 21-day cycle, between days −7 and −1 of a 21-day cycle, on day 1 of a 21-day cycle, or at least 40 hours prior to administration of the checkpoint inhibitor or Compound No. 14.

[0087] The following embodiments relate to both aspects of the invention.

[0088] In some embodiments, the checkpoint inhibitor is administered in an amount of 200 mg.

[0089] In some embodiments, Compound No. 14 is administered in an amount of 0.05 mg, 0.1 mg, 0.2 mg, 0.4 mg, 0.8 mg, 1.2 mg, 1.6 mg, 2.0 mg, or 2.5 mg.

[0090] In some embodiments, Compound No. 14 is administered in an amount of 0.05 mg to 3.5 mg, or in an amount of 0.1 mg to 3.5 mg, or in an amount of 0.2 mg to 2.5 mg, or in an amount of 0.05 mg to 1.2 mg, or in an amount of 0.1 mg to 1.2 mg, or in an amount of 0.2 mg to 1.2 mg.

[0091] In some embodiments, Compound No. 14, or a pharmaceutically acceptable salt thereof, and a checkpoint inhibitor are administered simultaneously once every 12 weeks, once every 4 weeks, once every 3 weeks, once every 2 weeks, once a week, twice a week, three times a week, daily, on days 1, 4, 8, and 11 of a 21 day cycle, or on days 1, 8, and 15 of a 21 day cycle.

[0092] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once every two weeks, once a week, twice a week, three times a week, daily, on days 1, 4, 8, and 11 of a 21 day cycle, or on days 1, 8, and 15 of a 21 day cycle, and a checkpoint inhibitor is separately administered once every 12 weeks, once every 4 weeks, once every 3 weeks, once every two weeks, once a week, twice a week, three times a week, or daily.

[0093] In one aspect, the present disclosure relates to a kit comprising a pharmaceutical agent for use in treating cancer in a subject in need thereof. The kit comprises a pharmaceutical agent comprising a STING agonist and instructions for administering the STING agonist and one or more checkpoint inhibitors, or the kit comprises a pharmaceutical agent comprising a STING agonist and instructions for administering the STING agonist, one or more checkpoint inhibitors, and radiation, or the kit comprises a pharmaceutical agent comprising one or more checkpoint inhibitors and instructions for administering one or more checkpoint inhibitors and a STING agonist, or the kit comprises a pharmaceutical agent comprising one or more checkpoint inhibitors and instructions for administering one or more checkpoint inhibitors, a STING agonist, and radiation. The kit can include both a pharmaceutical agent comprising a STING agonist and a pharmaceutical agent comprising one or more checkpoint inhibitors, as well as instructions for administering the STING agonist, one or more checkpoint inhibitors, and radiation. The kit can also include one or more additional therapeutic agents.

[0094] In one aspect, the present disclosure relates to a medicament for use in treating cancer in a subject in need thereof. The medicament comprises a STING agonist and one or more checkpoint inhibitors. The medicament can also comprise one or more additional therapeutic agents. [Brief explanation of the drawings]

[0095] [Figure 1] Figure 1 shows tumor growth curves as a function of time for vehicle, Compound No. 14, radiation only, and combination treatment groups in the EMT6 syngeneic tumor model from Study 1. Compound No. 14 was administered at 1.0 mg / kg every three days for three doses (Q3Dx3). Radiation was administered as a single dose of 10 Gy. [Figure 2]Figure 1 shows tumor growth curves as a function of time for vehicle, Compound No. 14, radiation only, and combination treatment groups in the EMT6 syngeneic tumor model from Study 2. Compound No. 14 was administered at 1.0 mg / kg every three days for three doses (Q3Dx3). Radiation was administered as a single dose of 10 Gy. [Figure 3a] Figure 1 shows survival curves as a function of time for vehicle, Compound No. 14, radiation alone, anti-mPD-1 antibody alone, and combination treatment in the EMT6 syngeneic tumor model from Study 3. Compound No. 14 was administered at 0.25 mg / kg or 1.0 mg / kg every three days for three doses (Q3D x 3). Anti-mPD-1 antibody or isotype control was administered at 10 mg / kg every three days for three doses (Q3D x 3). Radiation was administered at 8 Gy for three doses. Group 1 represents administration of vehicle (PBS), isotype control, and sham radiation. Group 2 represents administration of Compound No. 14 (1 mg / kg), isotype control, and sham radiation. Group 3 represents administration of Compound No. 14 (0.25 mg / kg), isotype control, and sham radiation. Group 4 represents administration of vehicle, anti-mPD-1 antibody, and sham radiation. Group 5 represents administration of vehicle, isotype control, and radiation (8 Gy x 3). Group 6 represents administration of Compound No. 14 (1 mg / kg), isotype control, and radiation (8 Gy x 3). Group 7 represents administration of vehicle, anti-mPD-1 antibody, and radiation (8 Gy x 3). Group 8 represents administration of Compound No. 14 (1 mg / kg), anti-mPD-1 antibody, and radiation (8 Gy x 3). Group 9 represents administration of Compound No. 14 (0.25 mg / kg), anti-mPD-1 antibody, and radiation (8 Gy x 3). [Figure 3b] Figure 1 shows tumor growth curves as a function of time for vehicle, Compound No. 14, radiation alone, anti-mPD-1 antibody alone, isotype control alone, and combination treatment groups in the EMT6 syngeneic tumor model from Study 3. Vehicle (PBS) or Compound No. 14 was administered at 0.25 mg / kg or 1.0 mg / kg every three days for three doses (Q3D x 3). Anti-mPD-1 antibody or isotype control was administered at 10 mg / kg every three days for three doses (Q3D x 3). Radiation was administered at 8 Gy for three doses. [Figure 4a]1 shows survival curves as a function of time for vehicle, Compound No. 14, anti-mPD-1 antibody alone, radiation alone, and combination treatment in the CT26 tumor model from Study 4. [Figure 4b] 1 shows tumor growth curves as a function of time for vehicle, Compound No. 14, anti-mPD-1 antibody only, radiation only, and combination treatment groups in the CT26 tumor model from Study 4. [Figure 5a] 1 shows survival curves as a function of time for vehicle, Compound No. 14, radiation only, and combination treatment in the B16F10 ova tumor model from Study 5. [Figure 5b] 1 shows tumor growth curves as a function of time for the vehicle, Compound No. 14, radiation only, and combination treatment groups of Study 5 in the B16F10 ova tumor model. DETAILED DESCRIPTION OF THE INVENTION

[0096] Definitions and Abbreviations To facilitate understanding of this disclosure, certain abbreviations, terms, and phrases are defined below.

[0097] [Table 1]

[0098] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications mentioned herein are incorporated by reference in their entirety.

[0099] As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissues, and / or the ability to establish new growth in ectopic locations. The term "cancer" includes solid tumors and non-solid tumors, such as hematologic tumors. The term "cancer" encompasses diseases of the skin, tissues, organs, bone, cartilage, blood, and vasculature. The term "cancer" further encompasses primary and metastatic cancers.

[0100] As used herein, the term "autoimmune disease" refers to a disorder resulting from an abnormal immune response against normal body parts. The term "autoimmune disease" encompasses disorders including, but not limited to, rheumatoid arthritis (RA), granulomatosis with polyglomerulitis (GPA) (Wegener's granulomatosis), and microscopic polyangiitis (MPA).

[0101] The terms "radiation" and "radiotherapy" are used interchangeably throughout this disclosure.

[0102] The term "PD-1" (also known as programmed cell death protein 1, PDCD1, CD279, SLEB2, or SLE1) refers to any native PD-1, unless otherwise indicated. The term "PD-1" encompasses "full-length," unprocessed PD-1, as well as any form of PD-1 that results from processing within cells. The term also encompasses naturally occurring variants of PD-1, such as splice variants, allelic variants, and isoforms.

[0103] The term "PD-L1" (also known as programmed cell death 1 ligand, unless otherwise indicated) refers to any naturally occurring PD-L1. The term "PD-L1" encompasses "full-length," unprocessed PD-L1, as well as any form of PD-L1 that results from processing within a cell. The term also encompasses naturally occurring variants of PD-L1, such as splice variants, allelic variants, and isoforms.

[0104] The term "CTLA-4" (also known as cytotoxic T-lymphocyte-associated antigen 4) refers to any native CTLA-4, unless otherwise indicated. The term "CTLA-4" encompasses "full-length," unprocessed CTLA-4, as well as any form of CTLA-4 that results from processing within a cell. The term also encompasses naturally occurring variants of CTLA-4, such as splice variants, allelic variants, and isoforms.

[0105] The term "antibody" refers to an immunoglobulin molecule that recognizes and binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination thereof, via at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term "antibody" encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) variants, multispecific antibodies, e.g., bispecific antibodies generated from at least two intact antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins containing an antigenic determinant of an antibody, and any other modified immunoglobulin molecule containing an antigen recognition site, so long as the antibody exhibits the desired biological activity. Antibodies can be any of five major immunoglobulin classes, namely, IgA, IgD, IgE, IgG, and IgM, or their subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the distinctive heavy chain constant domains designated alpha, delta, epsilon, gamma, and mu, respectively. Different classes of immunoglobulins have distinct and well-known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated to other molecules, such as toxins, radioisotopes, etc.

[0106] A "blocking" or "antagonist" antibody is an antibody that inhibits or reduces the biological activity of the antigen to which it binds, e.g., PD-1, PD-L1, or CTLA-4. In certain embodiments, a blocking or antagonist antibody substantially or completely inhibits the biological activity of the antigen. Desirably, the biological activity is reduced by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even 100%.

[0107] The terms "anti-PD-1 antibody" or "antibody that binds to PD-1" refer to an antibody that can bind to PD-1 with sufficient affinity so that the antibody is useful as a diagnostic and / or therapeutic agent in targeting PD-1. The extent of binding of the anti-PD-1 antibody to unrelated, non-PD-1 proteins is less than about 10% of the binding of the antibody to PD-1, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to PD-1 has a dissociation constant (Kd) of 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less.

[0108] The terms "anti-PD-L1 antibody" or "antibody that binds to PD-L1" refer to an antibody that can bind to PD-L1 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting PD-L1. The extent of binding of the anti-PD-L1 antibody to unrelated, non-PD-L1 proteins is less than about 10% of the binding of the antibody to PD-L1, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to PD-L1 has a dissociation constant (Kd) of 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less.

[0109] The terms "anti-CTLA-4 antibody" or "antibody that binds to CTLA-4" refer to an antibody that can bind to CTLA-4 with sufficient affinity so that the antibody is useful as a diagnostic and / or therapeutic agent in targeting CTLA-4. The extent of binding of the anti-CTLA-4 antibody to unrelated, non-CTLA-4 proteins is less than about 10% of the binding of the antibody to CTLA-4, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CTLA-4 has a dissociation constant (Kd) of 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less.

[0110] A "monoclonal antibody" refers to a homogeneous antibody that is involved in the highly antigen-specific recognition and binding of a single antigenic determinant, i.e., epitope. This is in contrast to polyclonal antibodies, which typically include different antibodies directed against different antigenic determinants. The term "monoclonal antibody" encompasses intact, full-length monoclonal antibodies, as well as antibody fragments (e.g., Fab, Fab', F(ab')2, Fv), single-chain (scFv) variants, fusion proteins containing an antibody portion, and any other immunoglobulin molecule containing an antigen-recognition site. Furthermore, "monoclonal antibody" refers to an antibody produced by any method, including, but not limited to, hybridoma, phage selection, recombinant expression, and transgenic animals.

[0111] The term "chimeric antibody" refers to an antibody in which the amino acid sequences of the immunoglobulin molecule are derived from two or more species. Typically, the variable regions of both the light and heavy chains correspond to the variable regions of antibodies from one species of mammal (e.g., mouse, rat, rabbit, etc.) having the desired specificity, affinity, and function, while the constant regions are homologous to the sequences of antibodies from another species (usually human) to avoid eliciting an immune response in that species.

[0112] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or a combination of one or more compounds that, when administered (e.g., sequentially or simultaneously), elicits a desired biological or pharmaceutical response, e.g., destroys target cancer cells or delays or arrests cancer progression in a patient. A therapeutically effective amount may vary depending on the intended use (in vitro or in vivo) or the patient and disease state being treated, e.g., the patient's weight and age, the severity of the disease state, the method of administration, etc., and can be readily determined by one of ordinary skill in the art. The term also applies to a dose that induces a specific response in target cells, e.g., reduced platelet adhesion and / or cell migration. For example, in some embodiments, a "therapeutically effective amount" as used herein refers to the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof, and the amount of a checkpoint inhibitor, when administered separately or in combination, that has a beneficial effect. In some embodiments, the combined effect is additive. In some embodiments, the combined effect is synergistic. Furthermore, one of skill in the art will recognize that in combination therapy, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof and / or the amount of checkpoint inhibitor may be used in a "sub-therapeutic amount," i.e., an amount that is less than the therapeutically effective amount of Compound No. 14 or a pharmaceutically acceptable salt thereof, or the checkpoint inhibitor alone.

[0113] In any form or composition, the administered dose(s) or therapeutically effective (total) amount may be: (i) BSA, e.g., mg / m 2 or (ii) on a mass basis, e.g., as mg, of the amount(s) of therapeutic agent(s) per patient.

[0114] The term "about" refers to approximately, within a range, roughly, or around. When the term "about" is used in conjunction with a numerical value or numerical range, it means that the referenced numerical value or numerical range is approximate within experimental variability (or within statistical experimental error); thus, the numerical value or numerical range may vary, for example, by 1% to 15% of the stated numerical value or numerical range. Generally, the term "about" is used herein to modify numerical values ​​above and below the stated value by a variance of ±10%.

[0115] As used herein, "patient" generally refers to a mammal (e.g., a human) who has been diagnosed with, exhibits, or is otherwise believed to be suffering from a disease, disorder, or condition (such as cancer).

[0116] As used herein, "body surface area" (BSA) is calculated using standard nomograms, e.g.,

[0117]

number

[0118] It is calculated using

[0119] The terms "co-administration," "administration in combination," and "administering a combination" refer to the administration of two or more pharmaceutically active ingredients (including, but not limited to, Compound No. 14 or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, or radiation, as disclosed herein) to a patient. Co-administration can refer to simultaneous or sequential administration of Compound No. 14 or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, and radiation, as disclosed herein.

[0120] The terms "simultaneous" and "concurrently" refer to administration of Compound No. 14, or a pharmaceutically acceptable salt thereof, and a checkpoint inhibitor, or administration of Compound No. 14, or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, and radiation, or any combination thereof, as disclosed herein, to a patient at the same time or at two or three different time points separated by no more than two hours. The simultaneous administration of Compound No. 14, or a pharmaceutically acceptable salt thereof, and a checkpoint inhibitor may be in a single dosage form or in separate dosage forms.

[0121] The terms "sequential" and "sequentially" refer to the administration of Compound No. 14, or a pharmaceutically acceptable salt thereof, and a checkpoint inhibitor, as disclosed herein, or Compound No. 14, or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, and radiation, as disclosed herein, or any combination thereof, to a patient at two or three different time points separated by more than two hours, for example, about 3 hours, about 4 hours, about 5 hours, about 8 hours, about 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or even longer.

[0122] The term "interruption" refers to a period following administration of one or more specific pharmaceutically active ingredients to a patient in an intermittent regimen. The interruption refers to a drug-free period during which the specific pharmaceutically active ingredient is not administered for at least one day.

[0123] The term "synergism" refers to a situation in which the effect of combining two or more drugs is greater than the sum of the effects of each drug individually. This term includes not only the alleviation of symptoms of the disorder being treated, but also an improved side effect profile, improved tolerability, improved patient compliance, increased efficacy, or any other improvement in clinical outcome.

[0124] The term "fractional dose" refers to the dose of radiation administered to each individual fraction.

[0125] As used herein, exemplary terms such as "include," "such as," "for example," etc. (and variations thereof, e.g., "includes," "including," "examples") are intended to be open-ended unless otherwise specified. That is, unless expressly stated otherwise, such terms are intended to imply "but not limited to," e.g., "including" means "including but not limited to."

[0126] Unless otherwise stated, structures depicted herein are also meant to include chemical entities that differ only in the presence of one or more isotopically enriched atoms, for example, the replacement of a hydrogen atom by deuterium or tritium, or 13 C- or 14 Chemical substances having the present structures except for the replacement of a carbon atom with a C-enriched carbon are within the scope of this invention.

[0127] Unless a stereochemical configuration is indicated, a structure depicted herein is meant to include all stereochemical forms of the structure, i.e., the R and S configurations for each asymmetric center. Thus, unless otherwise indicated, single stereochemical isomers as well as enantiomeric, racemic, and diastereomeric mixtures of the chemical compounds of the present invention are within the scope of the present invention. When the stereochemical configuration is indicated for a compound, the diastereomeric or enantiomeric excess of the compound is at least 99.0%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9%.

[0128] STING agonists The present disclosure provides a combination treatment for a patient with cancer or an autoimmune disease, which treatment comprises, inter alia, administering to a subject in need thereof a therapeutically effective amount of at least one STING agonist.

[0129] In some embodiments, the STING agonist is a compound of Formula I, having the following structure, or a pharmaceutically acceptable salt thereof:

[0130] [ka]

[0131] In the formula, R 1 and R 2 are each independently a hydroxy group or a halogen atom, B 1 teeth,

[0132] [ka]

[0133] and R 18 is hydrogen or C 1-6 is alkyl, R 19 is a halogen atom, B 2 teeth,

[0134] [ka]

[0135] and Q 2 and Q 4 are each independently an oxygen atom or a sulfur atom.

[0136] In some embodiments, the STING agonist is Compound No. 14, having the following structure, or a pharmaceutically acceptable salt thereof:

[0137] [ka]

[0138] In some embodiments, the STING agonist is Compound No. 14, or a pharmaceutically acceptable salt thereof.

[0139] In some embodiments, the STING agonist is Compound No. 14.

[0140] Certain STING agonists disclosed herein are described, for example, in PCT Publication No. WO2018 / 100558. They can be prepared by methods known to those of skill in the art and / or according to the methods described in WO2018 / 100558, which is incorporated herein by reference in its entirety.

[0141] In some embodiments, the STING agonist is Compound No. 14, or a crystalline form thereof.

[0142] Checkpoint inhibitors The present disclosure provides, inter alia, combination therapies comprising administering to a subject in need thereof a therapeutically effective amount of at least one checkpoint inhibitor (e.g., nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, and ipilimumab). In some embodiments, the checkpoint inhibitor is an anti-PD-1 antibody. In some embodiments, the checkpoint inhibitor is an anti-PD-L1 antibody. In some embodiments, the checkpoint inhibitor is an anti-CTLA-4 antibody.

[0143] PD-1 is a type I transmembrane protein that is one of the major immune checkpoint molecules (Blank et al., 2005, Cancer Immunotherapy, 54:307-314). PD-1 is primarily expressed on activated T cells, where it interacts with its ligands PD-L1 (B7-H1 or CD274) and PD-L2 (B7-DC or CD273) to induce inhibitory signals that result in reduced T cell proliferation, cytokine production, and cytotoxic activity (Freeman et al., 2000, J. Exp. Med., 192:1027-34).

[0144] In some embodiments, the anti-PD-1 antibody is a fully human monoclonal antibody. In some embodiments, the anti-PD-1 antibody is a humanized IgG monoclonal antibody.

[0145] In some embodiments, the anti-PD-1 antibody is a full-length (intact) antibody. In some embodiments, the anti-PD-1 antibody consists of an anti-PD-1 binding fragment, including, but not limited to, Fab, Fab', F(ab')2, and Fv fragments, single-chain Fv fragments, and single-chain domain fragments.

[0146] In some embodiments, the anti-PD-1 antibody is a derivatized antibody. In some embodiments, the anti-PD-1 antibody is derivatized by glycosylation, acetylation, PEGylation, phosphorylation, and amidation. In some embodiments, the anti-PD-1 antibody is derivatized by known protecting / blocking groups, proteolytic cleavage, or conjugation to a cellular ligand or other protein. In some embodiments, the derivatized anti-PD-1 antibody can also include one or more unnatural amino acids, for example, using ambrx technology (see, e.g., Wolfson, 2006, Chem. Biol. 13(10):1011-2).

[0147] In some embodiments, the anti-PD-1 antibody is nivolumab.

[0148] Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Nivolumab is an IgG4 kappa immunoglobulin with a calculated molecular weight of 146 kDa. It is expressed in a recombinant Chinese hamster ovary (CHO) cell line. Nivolumab has been approved by the FDA for the treatment of unresectable or metastatic melanoma, melanoma, metastatic non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer, and hepatocellular carcinoma. Nivolumab is commercially available as Opdivo®.

[0149] In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0150] Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Pembrolizumab is an IgG4 kappa immunoglobulin with a molecular weight of approximately 149 kDa. It is produced in recombinant Chinese hamster ovary (CHO) cells. It has been approved by the FDA for the treatment of melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, and cervical cancer. Pembrolizumab is commercially available as Keytruda®.

[0151] In some embodiments, the anti-PD-1 antibody is cemiplimab.

[0152] Cemiplimab is a human monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2. Cemiplimab is an IgG4 immunoglobulin with a molecular weight of approximately 146 kDa. Cemiplimab is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspensions. Cemiplimab is approved by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC that are not candidates for curative surgery or curative radiation. Cemiplimab is commercially available as Libtayo®.

[0153] Additional anti-PD-1 antibodies include, for example, pidilizumab (Medivation), BMS-936559 (Bristol-Myers Squibb), and AMP-224.

[0154] In some embodiments, the anti-PD-1 antibody used in the methods (and kits) described herein is nivolumab or an anti-PD-1 antibody that binds to the same epitope as nivolumab. In some embodiments, the anti-PD-1 antibody is nivolumab.

[0155] In some embodiments, the anti-PD-1 antibody used in the methods (and kits) described herein is pembrolizumab or an anti-PD-1 antibody that binds to the same epitope as pembrolizumab. In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0156] PD-L1 is a type I transmembrane protein containing an extracellular Ig-V-like domain, an Ig-C-like domain, a transmembrane domain, and an intracellular C-terminal domain. PD-L1 is frequently expressed in a wide range of cancers, including on tumor cells and / or tumor-infiltrating immune cells, and may contribute to the inhibition of antitumor immune responses in the tumor microenvironment. In some cancers, PD-L1 expression is associated with reduced survival and poor prognosis. PD-L1 is expressed on many cell types, including T cells, B cells, endothelial, epithelial, and antigen-presenting cells, cells of lung, liver, and heart tissue, and several types of tumor cells. PD-L1 expression on the cell surface has also been shown to be upregulated through IFN-γ stimulation. At least four variants of PD-1 have been cloned from activated human T cells, including transcripts lacking (i) exon 2, (ii) exon 3, (iii) exons 2 and 3, or (iv) exons 2–4. Nielsen et al., Cell. Immunol. 235:109-16 (2005). The amino acid sequence of human PD-L1 is represented by GenBank accession number NP054862.1.

[0157] In some embodiments, the anti-PD-L1 antibody is a full-length (intact) antibody. In some embodiments, the anti-PD-L1 antibody is comprised of an anti-PD-L1 binding fragment, including, but not limited to, Fab, F(ab')2, Fd, Fv, and dAb fragments, single-chain Fv fragments, and PD-L1 binding domain immunoglobulin fusion proteins.

[0158] In some embodiments, the anti-PD-L1 antibody is atezolizumab.

[0159] Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody. It is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin with a calculated molecular weight of 145 kDa. Atezolizumab has been approved by the FDA for the treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer. Atezolizumab is commercially available as Tecentriq®.

[0160] In some embodiments, the anti-PD-L1 antibody is durvalumab.

[0161] Durvalumab is a programmed cell death ligand 1 (PD-L1) blocking antibody. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension cultures. It has been approved by the FDA for the treatment of urothelial carcinoma and non-small cell lung cancer. Durvalumab is commercially available as Imfinzi®.

[0162] In some embodiments, the anti-PD-L1 antibody is avelumab.

[0163] Avelumab is a programmed death-ligand-1 (PD-L1) blocking antibody. It is a human IgG1 lambda monoclonal antibody with a molecular weight of approximately 147 kDa. Avelumab has been approved by the FDA for the treatment of metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. Avelumab is commercially available as Bavencio®.

[0164] Additional anti-PD-L1 antibodies include, for example, YW243.55.S70 (U.S. Patent No. 8,217,149), MEDI-4736, MSB-0010718C, LY3300054 (Eli Lilly and Co.), BMS-936559 (Bristol-Meyers Squibb), MPDL3280A, and MDX-1105.

[0165] In some embodiments, the anti-PD-L1 antibody used in the methods (and kits) described herein is atezolizumab or an anti-PD-L1 antibody that binds to the same epitope as atezolizumab, hi some embodiments, the anti-PD-L1 antibody is atezolizumab.

[0166] In some embodiments, the anti-PD-L1 antibody used in the methods (and kits) described herein is durvalumab or an anti-PD-L1 antibody that binds to the same epitope as durvalumab. In some embodiments, the anti-PD-L1 antibody is durvalumab.

[0167] In some embodiments, the anti-PD-L1 antibody used in the methods (and kits) described herein is avelumab or an anti-PD-L1 antibody that binds to the same epitope as avelumab. In some embodiments, the anti-PD-L1 antibody is avelumab.

[0168] CTLA-4 is a type I transmembrane protein encoded in humans by the CTLA-4 gene. CTLA-4 has been found to correlate with cancer growth and development due to its negative role in the immune response. CTLA-4 is expressed on the cell surface of activated CD4+ and CD8+ T cells and is a key negative regulator of T cell function. CTLA-4 has been shown to negatively regulate immune activation through both intrinsic and extrinsic mechanisms (Grosso and Kunkel, Cancer Immunity (2013) 13:5). Inhibition of CTLA-4 negative regulation has been shown to promote stimulation of adaptive immune responses and T cell activation. A representative amino acid sequence of human CTLA-4 can be found in GenBank accession number AAL07473.1, and a representative mRNA nucleic acid sequence encoding human CTLA-4 can be found in GenBank accession number AF414120.1.

[0169] In some embodiments, the anti-CTLA-4 antibody is a full-length (intact) antibody. In some embodiments, the anti-CTLA-4 antibody consists of an anti-CTLA-4 binding fragment, including, but not limited to, Fab, Fab', F(ab'), Fv, and single-chain fragments, diabodies, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (dsdiabodies), single-chain antibody molecules (scFv), scFv dimers (bivalent diabodies), multispecific antibodies, camelized single-domain antibodies, nanobodies, domain antibodies, and bivalent domain antibodies.

[0170] In some embodiments, the anti-CTLA-4 antibody is ipilimumab.

[0171] Ipilimumab is a recombinant human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with a molecular weight of approximately 148 kDa. Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture. Ipilimumab is approved by the FDA for the treatment of unresectable or metastatic melanoma, adjuvant treatment of melanoma, and advanced renal cell carcinoma. Ipilimumab is commercially available as Yervoy®.

[0172] Additional anti-CTLA-4 antibodies include, for example, tremelimumab.

[0173] In some embodiments, the anti-CTLA-4 antibody used in the methods (and kits) described herein is ipilimumab or an anti-CTLA-4 antibody that binds to the same epitope as ipilimumab, hi some embodiments, the anti-CTLA-4 antibody is ipilimumab.

[0174] radiation In some embodiments, the radiation is photon radiation (X-rays and gamma rays). In such embodiments, the photons are generated as a high-energy photon beam from a radioactive source such as a cobalt or linear accelerator.

[0175] In some embodiments, the radiation is particle radiation (such as electrons, protons, neutrons, carbon ions, alpha particles, and beta particles). The particle beam may be generated by a linear accelerator. In some embodiments, the radiation is an electron beam. In some embodiments, the radiation is a proton beam. In some embodiments, the radiation is a neutron beam.

[0176] In some embodiments, the radiation is delivered by external beam radiation. In some embodiments, the external beam radiation is three-dimensional conformal radiation therapy (3D-CRT). In some embodiments, the external beam radiation is intensity-modulated radiation therapy (IMRT). In some embodiments, the external beam radiation is image-guided radiation therapy (IGRT). In some embodiments, the external beam radiation is intensity-modulated proton therapy (IMPT). In some embodiments, the external beam radiation is stereotactic radiosurgery (SRS). In some embodiments, the external beam therapy is fractionated stereotactic radiation therapy. In some embodiments, the external beam radiation is stereotactic body radiation therapy (SBRT). Examples of machines that deliver SBRT are the Gamma Knife®, X-Knife®, CyberKnife®, and Clinac®. In some embodiments, the radiation can be administered using three-dimensional conformal or stereotactic body radiation therapy delivery.

[0177] In some embodiments, radiation is delivered by internal radiation therapy (brachytherapy). In such embodiments, internal radiation therapy is, for example, interstitial radiation using small pellets, seeds, wires, or tubes placed near the cancer or tumor site. In such embodiments, internal radiation therapy is, for example, intracavitary radiation using a container of radioactive material placed in a body cavity.

[0178] How to Treat Cancer In some embodiments, the present disclosure relates to a method of treating cancer in a patient by administering to a patient in need thereof a combination of a STING agonist, or a pharmaceutically acceptable salt thereof, and radiation.

[0179] In some embodiments, the present disclosure relates to a method of treating cancer in a patient by administering to a patient in need of such treatment a combination of a STING agonist or a pharmaceutically acceptable salt thereof, one or more checkpoint inhibitors, and radiation.

[0180] In some embodiments, the present disclosure relates to methods of treating cancer by administering a combination of a STING agonist, a checkpoint inhibitor, and radiation to a patient in need of such treatment.

[0181] In some embodiments, the present disclosure relates to the use of a STING agonist in combination with a checkpoint inhibitor and radiation for the treatment of cancer in a patient.

[0182] In some embodiments, the present disclosure relates to a composition comprising a STING agonist for use in treating cancer in a patient, where the patient is also treated with a checkpoint inhibitor and radiation. In some aspects, the present disclosure relates to a composition comprising a STING agonist for use in treating cancer in a patient, where the STING agonist is combined with a checkpoint inhibitor and radiation. In some embodiments, the STING agonist can be administered simultaneously or sequentially with the checkpoint inhibitor, radiation, and combinations thereof.

[0183] In some embodiments, the present disclosure relates to a method of treating cancer, comprising administering to a patient in need of such treatment therapeutically effective amounts of a combination of a STING agonist, a checkpoint inhibitor, and radiation.

[0184] In some embodiments, the present disclosure relates to methods of treating cancer by administering to a patient a combination of Compound No. 14, or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, and radiation.

[0185] In another aspect, the present disclosure relates to the use of Compound No. 14, or a pharmaceutically acceptable salt thereof, in combination with a checkpoint inhibitor and radiation for the treatment of cancer.

[0186] In some embodiments, the methods of treating cancer described herein can include a combination of a STING agonist, a checkpoint inhibitor, radiation, and one or more additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents can be a chemotherapeutic agent. In some embodiments, the one or more additional therapeutic agents can include, but are not limited to, fludarabine, cyclophosphamide, doxorubicin, vincristine, methotrexate, anthracycline chemotherapeutic agents, prednisone, methylprednisolone, glucocorticoids, ibritumomab tiuxetan, acetaminophen, antihistamines, and combinations thereof. In another embodiment, the checkpoint inhibitor is co-administered with human hyaluronidase.

[0187] In some embodiments, the present disclosure relates to a method of treating a disorder, wherein the disorder is cancer.

[0188] In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a metastatic solid tumor. In some embodiments, the cancer is an advanced solid tumor. Non-limiting examples of solid tumors include pancreatic cancer; bladder cancer, including invasive bladder cancer; colorectal cancer, including microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer; thyroid cancer; gastric cancer; breast cancer, including metastatic breast cancer and triple-negative breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; renal cancer, e.g., metastatic renal cell carcinoma and advanced renal cell carcinoma; urothelial carcinoma, including locally advanced or metastatic urothelial carcinoma; microsatellite-high unstable cancer; liver cancer, e.g., hepatocellular carcinoma and intrahepatic cholangiocarcinoma; non-small cell lung cancer (NSCLC), squamous lung carcinoma, bronchioloalveolar carcinoma (BAC), adenocarcinoma of the lung, and cancer of the head and neck, including squamous cell carcinoma of the head and neck, nasopharyngeal carcinoma, oral cavity and pharynx; melanoma, including unresectable or metastatic melanoma, and adjuvant treatment of melanoma; metastatic Merkel cell carcinoma; neuroendocrine carcinoma, including metastatic neuroendocrine tumors; brain tumors, including glioma / glioblastoma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; neuroendocrine carcinoma, including metastatic neuroendocrine tumors; osteosarcoma; gastroesophageal junction carcinoma, and soft tissue sarcoma.

[0189] In some embodiments, the cancer is a hematological cancer. Non-limiting examples of hematological malignancies that can be treated with the methods of the present disclosure include acute myeloid leukemia (AML); chronic myeloid leukemia (CML), including accelerated phase CML and blastic phase of CML (CML-BP); acute lymphoblastic leukemia (ALL); chronic lymphoblastic leukemia (CLL); Hodgkin lymphoma (HL), including classical Hodgkin lymphoma; non-Hodgkin lymphoma (NHL), including B-cell lymphoma, T-cell lymphoma, follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and Burkitt lymphoma; multiple myeloid leukemia (MML), including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), including acute myeloid leukemia (ALPHA), acute myeloid leukemia (ALPHA), chronic ... In some embodiments, the cancer is chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma, or non-Hodgkin's lymphoma, including follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and Burkitt's lymphoma.

[0190] In some embodiments, the cancer is melanoma, lung cancer, renal cancer, lymphoma, head and neck cancer, urothelial cancer, prostate cancer, bladder cancer, breast cancer, gastric cancer, colorectal cancer, leukemia, cervical cancer, microsatellite instability-high cancer, hepatocellular carcinoma, or Merkel cell carcinoma.

[0191] In some embodiments, the melanoma is metastatic melanoma, unresectable melanoma, or cutaneous melanoma.

[0192] In some embodiments, the lung cancer is non-small cell lung cancer or small cell lung cancer.

[0193] In some embodiments, the non-small cell lung cancer is metastatic non-small cell lung cancer, metastatic squamous non-small cell lung cancer, or metastatic non-squamous non-small cell lung cancer.

[0194] In some embodiments, the renal cancer is renal cell carcinoma.

[0195] In some embodiments, the lymphoma is classical Hodgkin's lymphoma or primary mediastinal large B-cell lymphoma.

[0196] In some embodiments, the head and neck cancer is head and neck squamous cell carcinoma.

[0197] In some embodiments, the urothelial cancer is urothelial carcinoma.

[0198] In some embodiments, the prostate cancer is hormone-refractory prostate cancer.

[0199] In some embodiments, the gastric cancer is gastroesophageal junction adenocarcinoma.

[0200] In some embodiments, the cancer is a microsatellite instability-high cancer.

[0201] In some embodiments, the cancer is triple-negative breast cancer.

[0202] In some embodiments, the cancer is a metastatic solid tumor.

[0203] In some embodiments, the cancer is recurrent. In some embodiments, a recurrent cancer is a cancer that has returned after a period of time during which the cancer was not detected.

[0204] In some embodiments, the cancer is refractory. In one aspect, a refractory cancer does not respond to cancer treatment, also known as a resistant cancer. In some embodiments, the cancer is resistant to rituximab. In some embodiments, the cancer does not respond to rituximab treatment. In some embodiments, the cancer is melanoma or colon cancer. In some embodiments, the patient has become refractory to a rituximab-containing regimen. In some embodiments, the tumor is unresectable. In some embodiments, an unresectable tumor cannot be removed by surgery. In some embodiments, the cancer has not been previously treated. In some embodiments, the cancer is locally advanced. In some embodiments, "locally advanced" refers to a cancer that is somewhat widespread but still limited to one area. In some cases, "locally advanced" can refer to a small tumor that has not spread but has invaded nearby organs or tissues, making it difficult to remove by surgery alone. In some embodiments, the cancer is metastatic. In some embodiments, a metastatic cancer is a cancer that has spread from the part of the body where it began (the primary site) to other parts of the body.

[0205] In some embodiments, the present disclosure relates to a method of treating a disorder, wherein the disorder is an autoimmune disease.

[0206] In some embodiments, the disorder is a STING-mediated disorder.

[0207] In some embodiments, the disorder is a PD-1 positive cancer. PD-1 positive cancers include cancers in which PD-1 is expressed in the cancer cells.

[0208] In some embodiments, the disorder is a PD-L1 positive cancer. PD-L1 positive cancers include cancers in which PD-L1 is expressed on the cancer cells.

[0209] In some embodiments, the disorder is a CTLA-4 positive cancer. CTLA-4 positive cancers include cancers in which CTLA-4 is expressed in the cancer cells.

[0210] Pharmaceuticals In some embodiments, the present disclosure relates to a medicament for use in treating cancer in a patient in need of such treatment. In some embodiments, the medicament comprises a STING agonist, in a single dosage form or in separate dosage forms. In some embodiments, the medicament comprises a STING agonist and a checkpoint inhibitor, in a single dosage form or in separate dosage forms.

[0211] In some embodiments, the medicaments described herein may include a combination of a STING agonist, a checkpoint inhibitor, and optionally one or more additional therapeutic agents.

[0212] In some embodiments, the disclosure relates to the use of a STING agonist in the manufacture of a medicament for treating cancer, wherein the STING agonist is administered together with a checkpoint inhibitor and radiation, and the medicaments are in a single dosage form or separate dosage forms. In some embodiments, the STING agonist is administered together with a checkpoint inhibitor, radiation, and one or more additional therapeutic agents.

[0213] In some embodiments, the disclosure relates to the use of a STING agonist for the manufacture of a medicament in the treatment of cancer in a patient, wherein the patient is also treated with a checkpoint inhibitor, radiation, and optionally one or more additional therapeutic agents. In some embodiments, the STING agonist can be administered simultaneously or sequentially with the checkpoint inhibitor, radiation, or a combination thereof. In some aspects, the disclosure relates to the use of a STING agonist for the manufacture of a medicament in the treatment of cancer in a patient, wherein the STING agonist is combined with a checkpoint inhibitor, radiation, and optionally one or more additional therapeutic agents. In some embodiments, the STING agonist is present in the same composition as the checkpoint inhibitor. In some embodiments, the STING agonist is present in a separate composition as the checkpoint inhibitor. In some embodiments, the STING agonist is present in the same composition as the one or more additional therapeutic agents. In some embodiments, the STING agonist is present in the same composition as the checkpoint inhibitor and, optionally, one or more additional therapeutic agents. In some embodiments, the STING agonist is present in a separate composition as the one or more additional therapeutic agents. In some embodiments, the STING agonist is present in a separate composition from the checkpoint inhibitor, and optionally one or more additional therapeutic agents.

[0214] In another aspect, the disclosure relates to the use of Compound No. 14, or a pharmaceutically acceptable salt thereof, in combination with a checkpoint inhibitor in the manufacture of a medicament for use in the treatment of cancer. In some embodiments, the disclosure relates to the use of Compound No. 14, or a pharmaceutically acceptable salt thereof, in combination with a checkpoint inhibitor, and optionally one or more additional therapeutic agents, in the manufacture of a medicament for use in the treatment of cancer.

[0215] In another aspect, the disclosure relates to the use of Compound No. 14, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer, wherein Compound No. 14, or a pharmaceutically acceptable salt thereof, is administered together with a checkpoint inhibitor, radiation, and optionally one or more additional therapeutic agents.

[0216] In some embodiments, the one or more additional therapeutic agents may be chemotherapeutic agents. In some embodiments, the one or more additional therapeutic agents may include, but are not limited to, fludarabine, cyclophosphamide, doxorubicin, vincristine, methotrexate, anthracycline chemotherapeutic agents, prednisone, methylprednisolone, glucocorticoids, ibritumomab tiuxetan, acetaminophen, antihistamines, and combinations thereof. In another embodiment, the checkpoint inhibitor is co-administered with human hyaluronidase.

[0217] Combination Administration Compound No. 14, or a pharmaceutically acceptable salt thereof, can be administered in combination with radiation, and optionally one or more additional therapeutic agents, in a single dosage form or as separate dosage forms.

[0218] Compound No. 14, or a pharmaceutically acceptable salt thereof, may be administered in combination with a checkpoint inhibitor, radiation, and optionally one or more additional therapeutic agents, in a single dosage form or as separate dosage forms. In some embodiments, when administered as separate dosage forms, the checkpoint inhibitor may be administered before, simultaneously with, or after administration of Compound No. 14, or a pharmaceutically acceptable salt thereof, and before, simultaneously with, or after administration of radiation. In some embodiments, when administered as separate dosage forms, one or more doses of Compound No. 14, or a pharmaceutically acceptable salt thereof, may be administered before the checkpoint inhibitor and radiation. In some embodiments, the checkpoint inhibitor is administered before administration of Compound No. 14, or a pharmaceutically acceptable salt thereof, and before radiation. In some embodiments, radiation is administered before the checkpoint inhibitor or before Compound No. 14 or a pharmaceutically acceptable salt thereof. In some embodiments, radiation is administered before the checkpoint inhibitor and before Compound No. 14, or a pharmaceutically acceptable salt thereof. In some embodiments, radiation is administered at least 40 hours prior to administration of the checkpoint inhibitor or Compound No. 14 or a pharmaceutically acceptable salt thereof. As used herein, administration of Compound No. 14 or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, radiation, and optionally one or more additional therapeutic agents in "concomitant" refers to simultaneous or sequential administration of the agents and radiation, as well as administration of the agents and radiation during a single treatment cycle, as would be understood by one of skill in the art. When Compound No. 14 or a pharmaceutically acceptable salt thereof is administered in combination with a checkpoint inhibitor, radiation, and optionally one or more additional therapeutic agents, a therapeutically effective amount of the combination is administered.

[0219] In some embodiments, Compound No. 14 and the checkpoint inhibitor are administered to the patient after radiation. In some embodiments, Compound No. 14 and the checkpoint inhibitor are administered to the patient who has previously been treated with radiation. In some embodiments, Compound No. 14 and the checkpoint inhibitor are administered to the patient 1 day to 3 months after the patient has been treated with radiation. In some embodiments, Compound No. 14 and the checkpoint inhibitor are administered to the patient 1 day to 3 months, or 1 day to 2 months, or 1 day to 1 month, or 1 day to 2 weeks, or 1 day to 1 week after the patient has been treated with radiation.

[0220] The STING agonist can be administered by any method known to those of skill in the art. For example, in some embodiments, the STING agonist can be administered in the form of a pharmaceutical composition of the STING agonist and a pharmaceutically acceptable carrier, such as those described herein. In some embodiments, the pharmaceutical composition is suitable for oral administration. In some embodiments, the pharmaceutical composition is a tablet or capsule suitable for oral administration. In some other embodiments, the pharmaceutical composition is a liquid dosage form suitable for oral administration. In some embodiments, the pharmaceutical composition is suitable for parenteral administration. In some embodiments, the pharmaceutical composition is suitable for intravenous administration. In some embodiments, the pharmaceutical composition is suitable for intravenous infusion. In some embodiments, the pharmaceutical composition is suitable for injection. In some embodiments, the pharmaceutical composition is suitable for intravenous injection. In some embodiments, the pharmaceutical composition is suitable for subcutaneous injection. In some embodiments, these compositions optionally further comprise one or more additional therapeutic agents.

[0221] The checkpoint inhibitor can be administered by any method known to one of skill in the art. In some embodiments, the checkpoint inhibitor is administered intravenously (iv). In some embodiments, the checkpoint inhibitor is administered subcutaneously (sc). In some embodiments, the checkpoint inhibitor is administered orally. For example, the checkpoint inhibitor can be administered in the form of a second composition, in some embodiments, a pharmaceutical composition of the checkpoint inhibitor, such as those described herein, and a pharmaceutically acceptable carrier. In one aspect, the pharmaceutical composition is suitable for oral administration. In some embodiments, the pharmaceutical composition is a tablet or capsule suitable for oral administration. In some other embodiments, the pharmaceutical composition is a liquid dosage form suitable for oral administration. In some embodiments, these compositions optionally further comprise one or more additional therapeutic agents.

[0222] Such pharmaceutical compositions of the present disclosure may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intravenous, intraperitoneal, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. In some embodiments, the checkpoint inhibitor is administered orally, intravenously, or subcutaneously. In some embodiments, the checkpoint inhibitor is administered orally. In some embodiments, the checkpoint inhibitor is administered intravenously. In some embodiments, intravenous administration can be intravenous infusion or intravenous injection. In some embodiments, the checkpoint inhibitor is administered by intravenous infusion. In some embodiments, the checkpoint inhibitor is administered by intravenous injection. In some embodiments, the checkpoint inhibitor is administered by subcutaneous injection. In some embodiments, the checkpoint inhibitor is administered by intravenous infusion followed by subcutaneous injection. In another embodiment, the checkpoint inhibitor is co-administered subcutaneously with human hyaluronidase. These administration methods can be designed to be short-acting, fast-releasing, or long-acting. Furthermore, the checkpoint inhibitor can be administered in a local manner, such as by injection at the tumor site, rather than systemically.

[0223] In some embodiments, the checkpoint inhibitors may be administered by nasal aerosol or inhalation. The checkpoint inhibitors may be prepared according to techniques well known in the art, and may be prepared as a solution in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0224] The amount or suitable dose of the disclosed methods depends on several factors, including the nature of the severity of the condition being treated, the particular inhibitor, the route of administration, and the age, weight, overall health, and response of the individual subject. In some embodiments, a suitable dose level is one that achieves a therapeutic response as measured by tumor regression or other standard measures of disease progression, progression-free survival, or overall survival. In some embodiments, a suitable dose level is one that achieves a therapeutic response while minimizing any side effects associated with the administration of the therapeutic agent. A suitable dose level may be one that prolongs the therapeutic response and / or prolongs lifespan.

[0225] It will be understood that the suitable doses of the STING agonist, checkpoint inhibitor, and optionally one or more additional therapeutic agents may be taken at any time of the day or night. In some embodiments, the suitable dose of each agent is administered in the morning. In some other embodiments, the suitable dose of each agent is administered in the evening. In some embodiments, the suitable dose of each agent is administered both in the morning and evening. It will be understood that the suitable dose of each agent may be administered with or without food. In some embodiments, the suitable dose of each agent is administered with a meal. In some embodiments, the suitable dose of each agent is administered on an empty stomach.

[0226] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on a daily schedule. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered every other day. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once every three days. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once every three days for a total of three doses. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on a twice-weekly schedule. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on a three-times-weekly schedule. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on a once-weekly schedule. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on a once-every-two-weekly schedule.

[0227] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered once daily. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered twice daily. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered three times daily.

[0228] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered at least three times every other day within a seven-day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1 and 4 within a seven-day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered consecutively within a seven-day cycle, followed by a break. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered for two consecutive days, followed by a break for five days within at least one seven-day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered for three consecutive days, followed by a break for four days within at least one seven-day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered for four consecutive days, followed by a break for three days within at least one seven-day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered for five consecutive days, followed by a break for two days within at least one seven-day cycle. In some embodiments, there will be a drug holiday between one or more 7 day treatment cycles. In some embodiments, there will be a drug holiday between one or more 7 day treatment cycles.

[0229] The present description contemplates administration of a STING agonist for one or more treatment cycles, e.g., 1, 2, 3, 4, 5, 6, or more treatment cycles. In some embodiments, the treatment cycle is about 7 days to about 56 days, or more. In some embodiments, the treatment cycle is 7, 14, 21, 28, 35, 42, 49, or 56 days. In some embodiments, the treatment cycle is 21 or 28 days. In some embodiments, there will be a drug holiday within or between one or more treatment cycles. For example, in some embodiments, there is a drug holiday at the end of a treatment cycle. In some embodiments, there is a drug holiday between the second and third treatment cycles, but not between the first and second treatment cycles. In other embodiments, there may be a drug holiday between the first and second treatment cycles, but not between the second and third treatment cycles. Dosing schedules include, for example, administering the STING agonist once during a treatment cycle, e.g., on day 1 of a 21-day cycle, twice during a treatment cycle, e.g., on days 1 and 15 of a 21-day cycle, or on days 1 and 15 of a 28-day cycle, three times during a treatment cycle, e.g., on days 1, 8, and 15 of a 21-day cycle, or on days 1, 8, and 15 of a 28-day cycle, and four times during a treatment cycle, e.g., on days 1, 4, 8, and 11 of a 21-day cycle, or on days 1, 4, 8, and 11 of a 28-day cycle. Other dosing schedules are encompassed by the invention.

[0230] In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered at least four times within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 1 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 4 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 8 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 11 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1, 4, 8, and 11 within a 21 day cycle.

[0231] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered within a 21 day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered at least twice within a 21 day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 1 within a 21 day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 8 within a 21 day cycle. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1 and 8 within a 21 day cycle.

[0232] In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered at least three times within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 1 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 8 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on day 15 within a 21 day cycle. In some embodiments, compound No. 14 or a pharmaceutically acceptable salt thereof is administered on days 1, 8, and 15 within a 21 day cycle.

[0233] In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered for a period of one year or less. In some embodiments, Compound No. 14 or a pharmaceutically acceptable salt thereof is administered for a period of one year or more.

[0234] In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 1000 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 300 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1 mg to about 300 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 3 mg to about 300 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 200 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1 mg to about 200 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 10 mg to about 200 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 100 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 50 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 10 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg to about 5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1 mg to about 3 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2 mg to about 5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 5 mg to about 10 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is from about 5 mg to about 15 mg.In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 10 mg to about 20 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 15 mg to about 25 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 20 mg to about 30 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 25 mg to about 35 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 30 mg to about 40 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 35 mg to about 45 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 40 mg to about 50 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 55 mg to about 65 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 50 mg to about 100 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 90 mg to about 150 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 140 mg to about 200 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 190 mg to about 250 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 240 mg to about 300 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 290 mg to about 350 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is from about 340 mg to about 400 mg.In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 390 mg to about 450 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 440 mg to about 500 mg.

[0235] In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 3 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 4 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 6 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 8 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 10 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 12 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 16 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 20 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 30 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 40 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 50 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 60 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 70 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 80 mg.In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 90 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 100 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 150 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 200 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 250 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 300 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 350 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 400 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 450 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 500 mg. All dosage amounts refer to the amount of Compound No. 14 administered and do not include the weight amount of any pharmaceutically acceptable salt.

[0236] In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.05 mg to about 3.5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.1 mg to about 3.5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.2 mg to about 3.5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.2 mg to about 2.5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.05 mg to about 1.2 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.1 mg to about 1.2 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.2 mg to about 1.2 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.05 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.1 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.2 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.4 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.8 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1.2 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1.6 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1.8 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2.0 mg.In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2.25 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2.5 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2.8 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 3.0 mg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 3.5 mg.

[0237] In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.01 mg / kg to about 100 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.01 mg / kg to about 50 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.01 mg / kg to about 20 mg / kg.

[0238] In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.01 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.05 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 0.1 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 1 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 2 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 4 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 6 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 8 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 10 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 12 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 14 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 16 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 18 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 20 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 30 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 40 mg / kg.In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 50 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 60 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 70 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 80 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 90 mg / kg. In some embodiments, the amount of Compound No. 14 or a pharmaceutically acceptable salt thereof administered on each day of administration is about 100 mg / kg.

[0239] In some embodiments, the checkpoint inhibitor is administered on a daily schedule. In some embodiments, the checkpoint inhibitor is administered every other day. In some embodiments, the checkpoint inhibitor is administered once every three days. In some embodiments, the checkpoint inhibitor is administered on a twice-weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a three-times-weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a once-every-two-weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a once-every-three-weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a once-every-four-weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a once-every-eight-weekly schedule. In some embodiments, the checkpoint inhibitor is administered on a once-every-12-weekly schedule.

[0240] In some embodiments, the checkpoint inhibitor is administered every other day at least three times within a 7-day cycle. In some embodiments, the checkpoint inhibitor is administered on day 1 of the treatment cycle. In certain embodiments, the checkpoint inhibitor is administered on days 1 and 4 of the 7-day cycle. In some embodiments, the checkpoint inhibitor is administered consecutively within a 7-day cycle followed by a break. In some embodiments, the checkpoint inhibitor is administered for two consecutive days followed by a break for five consecutive days within at least one 7-day cycle. In some embodiments, the checkpoint inhibitor is administered for three consecutive days followed by a break for four consecutive days within at least one 7-day cycle. In some embodiments, the checkpoint inhibitor is administered for four consecutive days followed by a break for three consecutive days within at least one 7-day cycle. In some embodiments, the checkpoint inhibitor is administered for five consecutive days followed by a break for two consecutive days within at least one 7-day cycle.

[0241] In some embodiments, the checkpoint inhibitor is administered on day 1 of a 21-day treatment cycle. In some embodiments, the checkpoint inhibitor is administered on day 2 of a 21-day treatment cycle. In some embodiments, the checkpoint inhibitor is administered on day 2 of the first 21-day treatment cycle and on day 1 of each 21-day treatment cycle thereafter.

[0242] The present description contemplates administration of a checkpoint inhibitor for one or more treatment cycles, e.g., 1, 2, 3, 4, 5, 6, or more treatment cycles. In some embodiments, the treatment cycle is about 7 days to about 84 days, or more. In some embodiments, the treatment cycle is 7, 14, 21, 28, 35, 42, 49, 56, or 84 days. In some embodiments, the treatment cycle is 21 or 28 days. In some embodiments, there will be a drug holiday within or between one or more treatment cycles. For example, in some embodiments, there is a drug holiday at the end of a treatment cycle. In some embodiments, there is a drug holiday between the second and third treatment cycles, but not between the first and second treatment cycles. In other embodiments, there may be a drug holiday between the first and second treatment cycles, but not between the second and third treatment cycles. Dosing schedules include, for example, administering the checkpoint inhibitor once during a treatment cycle, e.g., on day 1 of a 21 day cycle, twice during a treatment cycle, e.g., on days 1 and 15 of a 21 day cycle, or on days 1 and 15 of a 28 day cycle, three times during a treatment cycle, e.g., on days 1, 8, and 15 of a 21 day cycle, or on days 1, 8, and 15 of a 28 day cycle, and four times during a treatment cycle, e.g., on days 1, 4, 8, and 11 of a 21 day cycle, or on days 1, 4, 8, and 11 of a 28 day cycle. Other dosing schedules are encompassed by the invention.

[0243] In some embodiments, the checkpoint inhibitor is administered by subcutaneous injection. In some embodiments, the checkpoint inhibitor is administered by intravenous infusion followed by one or more subsequent subcutaneous injections. In some embodiments, the intravenous infusion and one or more subsequent subcutaneous injections are administered according to the dosing schedules and methods disclosed herein.

[0244] In some embodiments, both Compound No. 14 and the checkpoint inhibitor are administered on day 1 of a 21-day treatment cycle. In some embodiments, Compound No. 14 is administered first on day 1 of a 21-day treatment cycle, followed by administration of the checkpoint inhibitor. In some embodiments, Compound No. 14 is administered on day 1 of a 21-day treatment cycle, and the checkpoint inhibitor is administered on day 1 of the 21-day treatment cycle one hour after administration of Compound No. 14. In some embodiments, the checkpoint inhibitor is administered first on day 1 of a 21-day treatment cycle, followed by administration of Compound No. 14.

[0245] In some embodiments, radiation is administered first in a treatment cycle, the checkpoint inhibitor is administered second in a treatment cycle, and Compound No. 14 is administered third in a treatment cycle. In some embodiments, radiation is administered first in a treatment cycle, Compound No. 14 is administered second in a treatment cycle, and the checkpoint inhibitor is administered third in a treatment cycle. In some embodiments, radiation is administered first in a treatment cycle, followed by simultaneous administration of Compound No. 14 and the checkpoint inhibitor. In some embodiments, radiation is administered first in a treatment cycle, followed by sequential administration of Compound No. 14 and the checkpoint inhibitor. In some embodiments, radiation is administered before a treatment cycle, and the checkpoint inhibitor and Compound No. 14 are administered on day 1 of the treatment cycle. In some embodiments, radiation is administered before a treatment cycle, Compound No. 14 is administered on day 1 of the treatment cycle, and the checkpoint inhibitor is administered once every three weeks. In some embodiments, radiation is administered prior to a 21-day treatment cycle, compound number 14 is administered on days 1, 8, and 15 of the 21-day treatment cycle, and the checkpoint inhibitor is administered once every three weeks.

[0246] In some embodiments, Compound No. 14 is administered as a 60±10 minute intravenous infusion.

[0247] In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg to about 1000 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg to about 900 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg to about 800 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg to about 700 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg to about 600 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 1 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 10 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 50 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 100 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 150 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 220 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 240 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 260 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 280 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 300 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 320 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 340 mg to about 500 mg.In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 360 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 380 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 400 mg to about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 480 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 460 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 440 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 420 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 400 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 380 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 360 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 340 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 320 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg to about 300 mg.

[0248] In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 100 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 120 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 140 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 160 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 180 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 220 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 240 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 260 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 280 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 300 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 320 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 340 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 360 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 380 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 400 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 420 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 440 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 460 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 480 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 500 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 600 mg.In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 700 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 800 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 900 mg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 1000 mg.

[0249] In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 200 mg.

[0250] In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg / kg to about 7.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg / kg to about 5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 1 mg / kg to about 4 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 1 mg / kg to about 3 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 0.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 1 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 1.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 2 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 2.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 3 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 3.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 4 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 4.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 7.5 mg / kg. In some embodiments, the amount of anti-PD-1 antibody administered on each day of administration is about 10 mg / kg.

[0251] In some embodiments, the anti-PD-1 antibody is nivolumab or a pharmaceutically acceptable salt thereof. In some embodiments, the anti-PD-1 antibody is pembrolizumab or a pharmaceutically acceptable salt thereof. In some embodiments, the anti-PD-1 antibody is cemiplimab or a pharmaceutically acceptable salt thereof.

[0252] In some embodiments, the administration of nivolumab, pembrolizumab, and cemiplimab is in accordance with their prescribing information approved by a health authority, such as that issued by the FDA or EMA, which information is incorporated herein in its entirety.

[0253] In some embodiments, the anti-PD-1 antibody is pembrolizumab or a pharmaceutically acceptable salt thereof. In some embodiments, the amount of pembrolizumab administered on each day of administration is about 200 mg. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21-day cycle. In some embodiments, pembrolizumab is administered in an amount of 200 mg once every 3 weeks.

[0254] In some embodiments, the anti-PD-1 antibody is pembrolizumab, or a pharmaceutically acceptable salt thereof, and pembrolizumab is administered in combination with Compound No. 14 and radiation. In some embodiments, pembrolizumab is administered on day 1 of a 21 day cycle, Compound No. 14 is administered on days 1, 8, and 15 of the 21 day cycle, and radiation is administered on day 1 of the 21 day cycle or prior to the 21 day cycle. In some embodiments, pembrolizumab is administered on day 1 of a 21 day cycle, Compound No. 14 is administered on days 1, 8, and 15 of the 21 day cycle, and radiation is administered between days −8 and −1 of the 21 day cycle. In some embodiments, pembrolizumab is administered on day 1 of a 21 day cycle, compound number 14 is administered on days 1, 8, and 15 of the 21 day cycle, and radiation is administered between days −7 and −1 of the 21 day cycle. In some embodiments, pembrolizumab is administered on day 1 of a 21 day cycle, compound number 14 is administered on days 1, 8, and 15 of the 21 day cycle, and radiation is administered at least 40 hours prior to administration of pembrolizumab or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle, compound number 14 is administered in an amount of 0.1 mg on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle and compound number 14 is administered in an amount of 0.2 mg on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle and compound number 14 is administered in an amount of 0.2 mg or greater on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14.In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle, and compound number 14 is administered in an amount of 0.1 mg to 3.5 mg on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle, and compound number 14 is administered in an amount of 0.1 mg to 1.2 mg on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle, and compound number 14 is administered in an amount of 0.2 mg to 3.5 mg on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle, and compound number 14 is administered in an amount of 0.2 mg to 1.2 mg on days 1, 8, and 15 of the 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or compound number 14. In some embodiments, pembrolizumab is administered in an amount of 200 mg on day 1 of a 21 day cycle, Compound No. 14 is administered in an amount of 0.1 mg, 0.2 mg, 0.4 mg, 0.8 mg, 1.2 mg, 1.6 mg, 2.0 mg, 2.5 mg, 3.0 mg, or 3.5 mg on days 1, 8, and 15 of a 21 day cycle, and radiation is administered in fractionated doses of about 5 Gy to about 20 Gy at least 40 hours prior to administration of the checkpoint inhibitor or Compound No. 14.

[0255] In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg to about 1800 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg to about 1600 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg to about 1400 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg to about 1200 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg to about 1000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 100 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 200 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 400 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 600 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 800 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1200 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1500 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg to about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg to about 1800 mg.In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg to about 1600 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg to about 1400 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg to about 1200 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1200 mg to about 1400 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1100 mg to about 1300 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1100 mg to about 1200 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1200 mg to about 1300 mg.

[0256] In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 100 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 200 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 300 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 400 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 500 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 600 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 700 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 800 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 900 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1100 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1200 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1300 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1400 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1500 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1600 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1700 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1800 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1900 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 2000 mg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 2500 mg.In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 3000 mg.

[0257] In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 0.5 mg / kg to about 20 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1 mg / kg to about 20 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 5 mg / kg to about 20 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 5 mg / kg to about 15 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 5 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 6 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 7 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 8 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 9 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg / kg to about 15 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg / kg to about 14 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg / kg to about 13 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg / kg to about 12 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg / kg to about 11 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 1 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 2 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 3 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 4 mg / kg.In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 5 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 6 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 7 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 8 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 9 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 10 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 11 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 12 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 13 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 14 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 15 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 16 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 17 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 18 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 19 mg / kg. In some embodiments, the amount of anti-PD-L1 antibody administered on each day of administration is about 20 mg / kg.

[0258] In some embodiments, the anti-PD-L1 antibody is atezolizumab or a pharmaceutically acceptable salt thereof. In some embodiments, the anti-PD-L1 antibody is durvalumab or a pharmaceutically acceptable salt thereof. In some embodiments, the anti-PD-L1 antibody is avelumab or a pharmaceutically acceptable salt thereof.

[0259] In some embodiments, administration of atezolizumab, durvalumab, and avelumab is in accordance with their prescribing information approved by a health authority, such as that issued by the FDA or EMA, which information is incorporated herein in its entirety.

[0260] In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 0.5 mg to about 2000 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg to about 2000 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 10 mg to about 2000 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 50 mg to about 2000 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 100 mg to about 2000 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 10 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 100 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 200 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 400 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 600 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 800 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1000 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1200 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1400 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1600 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1800 mg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 2000 mg.

[0261] In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 0.5 mg / kg to about 20 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg to about 20 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg to about 18 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg to about 16 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg to about 14 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg to about 12 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg to about 10 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 1 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 2 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 3 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 4 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 5 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 6 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 7 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 8 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 9 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 10 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 11 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 12 mg / kg.In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 13 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 14 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 15 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 16 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 17 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 18 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 19 mg / kg. In some embodiments, the amount of anti-CTLA-4 antibody administered on each day of administration is about 20 mg / kg.

[0262] In some embodiments, the anti-CTLA-4 antibody is ipilimumab or a pharmaceutically acceptable salt thereof.

[0263] In some embodiments, administration of ipilimumab is in accordance with its prescribing information approved by a health authority, such as that issued by the FDA or EMA, which information is incorporated herein in its entirety.

[0264] In some embodiments, the radiation is particle radiation.

[0265] In some embodiments, the radiation is administered by external beam radiation.

[0266] In some embodiments, radiation is administered between day -15 and day 2 of the treatment cycle. In some embodiments, radiation is administered between day -10 and day 1 of the treatment cycle. In some embodiments, radiation is administered between day -10 and day 0 of the treatment cycle. In some embodiments, radiation is administered between day -10 and day -1 of the treatment cycle. In some embodiments, radiation is administered between day -9 and day -1 of the treatment cycle. In some embodiments, radiation is administered between day -8 and day -1 of the treatment cycle. In some embodiments, radiation is administered between day -7 and day -1 of the treatment cycle. In some embodiments, the treatment cycle is 21 days.

[0267] In some embodiments, radiation is administered at least 5 hours prior to administration of the checkpoint inhibitor or Compound No. 14. In some embodiments, radiation is administered at least 10 hours prior to administration of the checkpoint inhibitor or Compound No. 14. In some embodiments, radiation is administered at least 20 hours prior to administration of the checkpoint inhibitor or Compound No. 14. In some embodiments, radiation is administered at least 40 hours prior to administration of the checkpoint inhibitor or Compound No. 14. In some embodiments, radiation is administered at least 80 hours prior to administration of the checkpoint inhibitor or Compound No. 14.

[0268] In some embodiments, radiation is administered on days 1-5 of each week repeated for 2-8 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 6-8 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 2 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 3 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 4 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 5 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 6 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 7 weeks. In some embodiments, radiation is administered on days 1-5 of each week repeated for 8 weeks.

[0269] In some embodiments, radiation is administered on any two of days 1-5 of each week repeated for 5-8 weeks. In some embodiments, radiation is administered on any two of days 1-5 of each week repeated for 6-8 weeks. In some embodiments, radiation is administered on any two of days 1-5 of each week repeated for 5 weeks. In some embodiments, radiation is administered on any two of days 1-5 of each week repeated for 6 weeks. In some embodiments, radiation is administered on any two of days 1-5 of each week repeated for 7 weeks. In some embodiments, radiation is administered on any two of days 1-5 of each week repeated for 8 weeks.

[0270] In some embodiments, radiation is administered in fractional doses of about 1 Gy to about 100 Gy. In some embodiments, radiation is administered in fractional doses of about 1 Gy to about 50 Gy. In some embodiments, radiation is administered in fractional doses of about 1 Gy to about 20 Gy. In some embodiments, radiation is administered in fractional doses of about 5 Gy to about 20 Gy. In some embodiments, radiation is administered in fractional doses of about 6 Gy to about 18 Gy. In some embodiments, radiation is administered in fractional doses of about 8 Gy to about 16 Gy. In some embodiments, radiation is administered in fractional doses of about 5 Gy to about 10 Gy. In some embodiments, radiation is administered in fractional doses of about 10 Gy to about 15 Gy. In some embodiments, radiation is administered in fractional doses of about 15 Gy to about 20 Gy. In some embodiments, radiation is administered in fractional doses of about 1 Gy. In some embodiments, radiation is administered in fractional doses of about 2 Gy. In some embodiments, radiation is administered in fractional doses of about 3 Gy. In some embodiments, radiation is administered in fractional doses of about 4 Gy. In some embodiments, radiation is administered in fractional doses of about 5 Gy. In some embodiments, radiation is administered in fractional doses of about 6 Gy. In some embodiments, radiation is administered in fractional doses of about 7 Gy. In some embodiments, radiation is administered in fractional doses of about 8 Gy. In some embodiments, radiation is administered in fractional doses of about 9 Gy. In some embodiments, radiation is administered in fractional doses of about 10 Gy. In some embodiments, radiation is administered in fractional doses of about 11 Gy. In some embodiments, radiation is administered in fractional doses of about 12 Gy. In some embodiments, radiation is administered in fractional doses of about 13 Gy. In some embodiments, radiation is administered in fractional doses of about 14 Gy. In some embodiments, radiation is administered in fractional doses of about 15 Gy. In some embodiments, radiation is administered in fractional doses of about 16 Gy. In some embodiments, radiation is administered in fractional doses of about 17 Gy. In some embodiments, radiation is administered in fractional doses of about 18 Gy. In some embodiments, radiation is administered in fractional doses of about 19 Gy.In some embodiments, radiation is administered in fractional doses of about 20 Gy, hi some embodiments, radiation is administered in fractional doses of about 8 Gy or about 16 Gy.

[0271] In some embodiments, radiation is administered in fractions. In some embodiments, radiation is administered in 1 to 10 fractions. In some embodiments, radiation is administered in 1 to 5 fractions. In some embodiments, radiation is administered in 1 fraction, or 2 fractions, or 3 fractions, or 4 fractions, or 5 fractions. In some embodiments, radiation is administered in 1 or 3 fractions.

[0272] In some embodiments, radiation is administered in 1-3 fractions at a fractional dose of about 1-5 Gy. In some embodiments, radiation is administered in 1-3 fractions at a fractional dose of about 5-10 Gy. In some embodiments, radiation is administered in 1-3 fractions at a fractional dose of about 10-15 Gy. In some embodiments, radiation is administered in 1-3 fractions at a fractional dose of about 15-20 Gy. In some embodiments, radiation is administered in 1-3 fractions at a fractional dose of about 5-10 Gy, or in 1-3 fractions at a fractional dose of 15-20 Gy. In some embodiments, radiation is administered in 1 fraction at a fractional dose of about 8 Gy. In some embodiments, radiation is administered in 3 fractions at a fractional dose of about 8 Gy. In some embodiments, radiation is administered in 1 fraction at a fractional dose of about 16 Gy. In some embodiments, radiation is administered in one fraction at a fractional dose of about 8 Gy, or three fractions at a fractional dose of about 8 Gy, or one fraction at a fractional dose of about 16 Gy.

[0273] Pharmaceutical Compositions The STING agonists used in the methods and kits described herein may be formulated into pharmaceutical compositions suitable for administration.

[0274] The STING agonists and checkpoint inhibitors used in the methods and kits described herein can be formulated into pharmaceutical compositions suitable for administration. Pharmaceutical compositions may contain pharmaceutically acceptable excipients. As used herein, pharmaceutically acceptable excipients include, but are not limited to, any solvent, dispersion medium, or other liquid vehicle, dispersion or suspension aid, diluent, granulating and / or dispersing agent, surfactant, isotonicity agent, thickener or emulsifier, preservative, binder, lubricant or oil, colorant, sweetener or flavoring agent, stabilizer, antioxidant, antibacterial or antifungal agent, osmolality adjuster, pH adjuster, buffer, chelating agent, cryoprotectant, and / or bulking agent, suitable for the particular dosage form desired. Various excipients for formulating pharmaceutical compositions and techniques for preparing compositions are known in the art (Remington: The Science and Practice of Pharmacy, 21 st Ed., A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD), 2006, which is incorporated by reference in its entirety.

[0275] Any of the therapeutic agents described herein may take the form of a pharmaceutically acceptable salt. In some embodiments, such salts are derived from inorganic or organic acids or bases. For reviews of suitable salts, see, for example, Berge et al., J. Pharm. Sci., 1977, 66, 1-19, and Remington: The Science and Practice of Pharmacy, 20th Ed., A. Gennaro (ed.), Lippincott Williams & Wilkins (2000).

[0276] Examples of suitable acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.

[0277] Examples of suitable base addition salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, dicyclohexylamine salts, salts with organic bases such as N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and the like.

[0278] For example, Berge lists the following FDA-approved commercially available salts: anions acetate, besylate (benzenesulfonate), benzoate, bicarbonate, bitartrate, bromide, calcium edetate (ethylenediaminetetraacetate), camsylate (camphorsulfonate), carbonate, chloride, citrate, dihydrochloride, edetate (ethylenediaminetetraacetate), edisylate (1,2-ethanedisulfonate), estradiol, and estradiol. Lauryl sulfate, esylate (ethanesulfonate), fumarate, gluceptate (glucoheptonate), gluconate, glutamate, glycolyl arsanilate (glycolamidophenylarsonate), hexylresorcinate, hydrabamine (N,N'-di(dehydroabietyl)ethylenediamine), hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate ionate (2-hydroxyethanesulfonate), lactate, lactobionate, malate, maleate, mandelate, mesylate (methanesulfonate), methyl bromide, methyl nitrate, methyl sulfate, mucate, napsylate (2-naphthalenesulfonate), nitrate, pamoate (embonate), pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, diacetate, succinate, sulfate, tannate, tartrate, teoclate (8-chlorotheophyllinate), and triethiodide; the organic cations benzathine (N,N'-dibenzylethylenediamine), chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine; and the metal cations aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.

[0279] Berge further lists the following non-FDA approved commercially available (outside the United States) salts: the anions adipate, alginate, aminosalicylate, anhydromethylene citrate, arecoline, aspartate, bisulfate, butyl bromide, camphorate, digluconate, dihydrobromide, disuccinate, glycerophosphate, hemisulfate, hydrogen fluoride, hydroiodide, methylene bis(salicylate), napadisilate (1,5-naphthalenedisulfonate), oxalate, and pectinate. , persulfate, phenylethylbarbiturate, picrate, propionate, thiocyanate, tosylate, and undecanoate, the organic cations benethamine (N-benzylphenethylamine), clemizole (1-p-chlorobenzyl-2-pyrrolidin-1'-ylmethylbenzimidazole), diethylamine, piperazine, and tromethamine (tris(hydroxymethyl)aminomethane), and the metal cations barium and bismuth.

[0280] The pharmaceutical composition may include a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" refers to a substance that is compatible with the recipient subject (human) and suitable for delivering the active agent to the target site without terminating the activity of the agent. If any, the toxicity or adverse effects associated with the carrier are preferably commensurate with a reasonable risk-benefit ratio for the intended use of the active agent.

[0281] Pharmaceutically acceptable carriers that may be used in these compositions include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates or carbonates, saturated vegetable fatty acids such as glycine, sorbic acid, potassium sorbate, protamine sulfate, water, salts, or partial glyceride mixtures of electrolytes, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic materials, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.

[0282] Pharmaceutical compositions for use in the methods of the present disclosure can be prepared by methods well known in the art, such as conventional granulation, mixing, dissolving, encapsulation, lyophilization, or emulsification processes, among others. The compositions can be produced in a variety of forms, including granules, precipitates, or particulates, powders, including freeze-dried, rotary-dried, or spray-dried powders, amorphous powders, tablets, capsules, syrups, suppositories, injections, emulsions, elixirs, suspensions, or solutions. Formulations may contain stabilizers, pH adjusters, surfactants, solubilizers, bioavailability modifiers, and combinations thereof. These pharmaceutical compositions are formulated for pharmaceutical administration to humans. Such compositions can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intravenous, intraperitoneal, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. In some embodiments, the compositions are administered orally, intravenously, or subcutaneously. In some embodiments, the compositions are administered orally. In some embodiments, the compositions are administered intravenously. In some embodiments, intravenous administration can be intravenous infusion or intravenous injection. In some embodiments, the compositions are administered by intravenous infusion. In some embodiments, the compositions are administered by intravenous injection. In some embodiments, the compositions are administered by subcutaneous injection. In some embodiments, the compositions are administered by intravenous infusion followed by subcutaneous injection. In another embodiment, a checkpoint inhibitor is co-administered subcutaneously with human hyaluronidase. These formulations can be designed to be short-acting, fast-releasing, or long-acting. Additionally, the compositions can be administered in a local manner, such as by administration (e.g., by injection) at the tumor site, rather than systemically.

[0283] Pharmaceutical formulations can be prepared as liquid suspensions or solutions using liquids such as oil, water, alcohol, and combinations thereof. Solubilizers such as cyclodextrins can be included. Pharmaceutically suitable surfactants, suspending agents, or emulsifiers can be added for oral or parenteral administration. Suspensions can include oils such as peanut oil, sesame oil, cottonseed oil, corn oil, and olive oil. Suspension formulations can also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides, and acetylated fatty acid glycerides. Suspension formulations can include alcohols such as ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol, and propylene glycol, ethers such as poly(ethylene glycol), petroleum hydrocarbons such as mineral oil and mineral oil, and water.

[0284] Sterile injectable forms of these pharmaceutical compositions may be aqueous or oily suspensions. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that may be used include water, Ringer's solution, and physiological saline solution. Additionally, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland fixed oil may be used, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils such as olive oil or castor oil, particularly in their polyoxyethylated versions. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions or suspensions. Other commonly used surfactants, such as sorbitan alkyl esters, such as Tween or Span, and other emulsifiers or bioavailability enhancers commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms, can also be used for formulation purposes. The composition can be formulated for parenteral administration by injection, for example, bolus injection or continuous infusion. The unit dosage form for injection can be in ampoules or multi-dose containers.

[0285] These pharmaceutical compositions can be orally administered in any orally acceptable dosage form, including capsules, tablets, aqueous suspensions, or solutions. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring, or coloring agents can also be added. For oral administration in capsule form, useful diluents include lactose and dried cornstarch. For tablets for oral use, commonly used carriers include lactose and cornstarch. Lubricants, such as magnesium stearate, are also typically added. Coatings can be used for various purposes, such as masking taste, affecting the site of dissolution or absorption, or prolonging the action of the drug. Coatings can be applied to tablets or to granulated particles for use in capsules.

[0286] Alternatively, these pharmaceutical compositions can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore melts in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[0287] These pharmaceutical compositions may also be administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, such as diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0288] Topical application for the lower intestinal tract can be achieved with a rectal suppository formulation (see above) or a suitable enema formulation. A topical transdermal patch can also be used. For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present disclosure include mineral oil, liquid mineral oil, white mineral oil, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water. Alternatively, the pharmaceutical composition can be formulated into a suitable lotion or cream containing the active ingredient(s) suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0289] For ophthalmic use, the pharmaceutical composition may be formulated as a micronized suspension in isotonic, pH-adjusted, sterile saline, or preferably as a solution in isotonic, pH-adjusted, sterile saline, either with or without a preservative, such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated into an ointment, such as petrolatum.

[0290] Pharmaceutical compositions may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation, and may be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0291] In one embodiment, Compound No. 14 is formulated as a solution for intravenous infusion. In some embodiments, Compound No. 14 is formulated in a solution containing 3 mg / 3 mL of Compound No. 14 as the free base. In one embodiment, the solution of Compound No. 14 can be diluted prior to infusion.

[0292] kit In some embodiments, the STING agonists or checkpoint inhibitors described herein can be manufactured for inclusion in a kit. A "kit" is any article of manufacture (e.g., a package or container) containing at least one reagent or chemotherapeutic agent. Kits for use in the methods herein can include a STING agonist, e.g., Compound No. 14, or a pharmaceutically acceptable salt thereof. In some embodiments, the kit can further include a checkpoint inhibitor, and optionally one or more additional therapeutic agents. In some embodiments, the kit can include Compound No. 14, or a pharmaceutically acceptable salt thereof, a checkpoint inhibitor, and optionally one or more additional therapeutic agents. In some embodiments, the kit can include one or more STING agonists, or a pharmaceutically acceptable salt thereof. In some embodiments, the kit can include one or more checkpoint inhibitors. In some embodiments, the kit can further include instructions for administering radiation.

[0293] In some embodiments, the present disclosure relates to kits containing pharmaceuticals for use in treating cancer in patients in need of such treatment. The kits include a pharmaceutical comprising a STING agonist and instructions for administering the STING agonist and a checkpoint inhibitor, or the kits include a pharmaceutical comprising a checkpoint inhibitor and instructions for administering the checkpoint inhibitor and the STING agonist. The kits may also include a pharmaceutical comprising a STING agonist, instructions for administering the STING agonist and the checkpoint inhibitor, and instructions for administering radiation, or the kits may include a pharmaceutical comprising a checkpoint inhibitor, instructions for administering the checkpoint inhibitor and the STING agonist, and instructions for administering radiation. The kits may include a pharmaceutical comprising a STING agonist and a checkpoint inhibitor, and instructions for administering the STING agonist and the checkpoint inhibitor, where the pharmaceuticals are in a single dosage form or in separate dosage forms. The kit may also include a medicament comprising a STING agonist and a checkpoint inhibitor, instructions for administering the STING agonist and the checkpoint inhibitor, and instructions for administering radiation, where the medicaments are in a single dosage form or in separate dosage forms. In some embodiments, the kit optionally includes one or more additional therapeutic agents.

[0294] In some embodiments, a kit comprising a STING agonist and a checkpoint inhibitor, or a kit comprising a STING agonist, a checkpoint inhibitor, and instructions for administering radiation, may further comprise additional components or reagents. In some embodiments, a reagent in the kit may be a diluent for preparing the STING agonist for administration. In some embodiments, a reagent in the kit may be a diluent for preparing the checkpoint inhibitor for administration. In some embodiments, a component in the kit may be a container for mixing the combination of the STING agonist and the checkpoint inhibitor.

[0295] In another aspect, the present disclosure relates to a kit for treating cancer, the kit comprising at least one medicament comprising at least one dose of Compound No. 14 or a pharmaceutically acceptable salt thereof, and at least one medicament comprising at least one dose of a checkpoint inhibitor, the kit for treating cancer further comprising administration instructions for administering the medicaments for treatment of a patient identified in need thereof. In another aspect, the present disclosure relates to a kit for treating cancer, the kit comprising at least one medicament comprising at least one dose of Compound No. 14 or a pharmaceutically acceptable salt thereof, at least one medicament comprising at least one dose of a checkpoint inhibitor, and instructions for administering radiation, the kit further comprising administration instructions for administering the medicaments and radiation for treatment of a patient identified in need thereof. [Example]

[0296] In order that this disclosure may be more fully understood, the following examples are set forth. These examples are illustrative only and are not intended to limit the scope of the disclosure in any way.

[0297] [Table 2-1]

[0298] [Table 2-2]

[0299] Example 1: In vivo tumor efficacy General experimental conditions for antitumor efficacy in mouse tumor models Mouse syngeneic tumor model The following syngeneic models were utilized in each of Studies 1-3, as specified below.

[0300] Studies 1 and 2: EMT6 is a mouse breast cancer cell line. The EMT6 mouse syngeneic tumor model was established in 9-10 week-old female BALB / c mice (Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) at 0.2 × 10 6 EMT6 cells (cell suspension) were inoculated subcutaneously (sc) into the flank. In Study 1, the mean tumor volume was 60 mm 3 and in Study 2, the mean tumor volume was 75 mm 3 When the tumor size reached 100 mg / kg, animals were randomized into one vehicle control group and seven treatment groups (n=10 / group). Mice were then administered vehicle (phosphate-buffered saline (PBS)), Compound No. 14, 10 Gy radiation, or Compound No. 14 + 10 Gy radiation for 8 days. Tumor growth and body weight were measured three times weekly during the treatment and post-treatment periods. Mice were humanely euthanized after reaching the humane endpoint or at the end of the study on day 72 (Study 1) or day 60 (Study 2).

[0301] Study 3: EMT6 is a mouse breast cancer cell line. The EMT6 mouse syngeneic tumor model was grown in the mammary fat pad of 7-8 week-old female BALB / c mice (Envigo Corp., Indianapolis, IN) at 1.0 × 10 6 The tumors were generated by orthotopic inoculation of EMT6 cells (cell suspension). The average tumor volume was approximately 110 mm. 3 When the NIH score reached 0.05, animals were randomized into one vehicle control group and eight treatment groups (n=8 / group). Mice were then treated with Compound #14, anti-mouse PD-1 (anti-mPD-1) (clone RMP1-14), and / or three fractionated doses of 8 Gy of radiation (8 Gy x 3), or the respective control agents (PBS, isotype control antibody, and / or sham radiation) in the following combinations for 11 days:

[0302] Group 1: Vehicle (PBS) + isotype control + sham radiation

[0303] Group 2: Compound No. 14 (1 mg / kg) + isotype control + sham radiation

[0304] Group 3: Compound No. 14 (0.25 mg / kg) + isotype control + sham radiation

[0305] Group 4: Vehicle + anti-mPD-1 + sham radiation

[0306] Group 5: vehicle + isotype control + radiation (8 Gy x 3)

[0307] Group 6: Compound No. 14 (1 mg / kg) + isotype control + radiation (8 Gy x 3)

[0308] Group 7: Vehicle + anti-mPD-1 + radiation (8 Gy × 3)

[0309] Group 8: Compound No. 14 (1 mg / kg) + anti-mPD-1 + radiation (8 Gy × 3)

[0310] Group 9: Compound No. 14 (0.25mg / kg) + anti-mPD-1 + radiation (8Gy×3)

[0311] Tumor growth and body weight were measured three times a week during the treatment and post-treatment periods. Mice were humanely euthanized after reaching the humane endpoint. Mice with complete regression were evaluated until day 74 or day 108.

[0312] Study 4: CT26 is a mouse colon cancer cell line. Eight-week-old female Balb / c mice (Jackson Labs, Maine) were inoculated with 0.2 × 10 6 CT26 tumor cells were inoculated subcutaneously and tumor growth was monitored. Tumors averaged 100-125 mm 3Once the tumor reached the humane endpoint, the animals were irradiated with either sham irradiation or 8 Gy focal beam irradiation (study day 0). The animals were then intravenously administered either vehicle (PBS) or 0.25 mg / kg of Compound #14 on a QWx3 schedule starting on study day 1. Anti-mPD-1 antibody (clone RMP1-14, BioXCell) treatment was administered intraperitoneally at 10 mg / kg twice weekly for 3 weeks, starting on study day 1. After the animals reached the humane endpoint, tumor volume and weight changes were monitored twice weekly throughout the study. GRI was calculated on the final day (study day 11) using the remaining animals in the vehicle group.

[0313] Study 5: B16F10-Ova is a B16F10 melanoma-derived cell line expressing chicken ovalbumin. Seven-week-old female C57Bl / 6 mice (Jackson Labs, Maine) were inoculated with 0.04 × 10 6 B16F10 ova tumor cells were inoculated subcutaneously and monitored for tumor growth. Tumors averaged 100-250 mm 3 Once the tumor reached the target tumor volume (GRI), the animals were irradiated with either sham irradiation or 16 Gy focal beam irradiation (Study Day 0). The animals were then intravenously administered either vehicle (PBS) or 0.25 mg / kg of Compound No. 14 on a Q3Dx3 schedule starting on Study Day 1. After the animals reached the humane endpoint, they were monitored for tumor volume and weight changes twice weekly throughout the study. The GRI was calculated on the final day (Study Day 10) using the remaining animals in the vehicle group.

[0314] Test drug The following test agents were used in Studies 1-3, as specified below:

[0315] Studies 1 and 2: A 0.1 mg / mL stock solution of Compound No. 14 was formulated in PBS and administered intravenously (IV) using a dose volume of 10 mL / kg body weight based on the exact animal weight on each day of treatment. The final dose received was 1.0 mg / kg. Compound No. 14 dose volume did not exceed 0.2 mL. Compound No. 14 was administered on a Q3D schedule of three doses (days 2, 5, and 8) in the single-agent and combination treatment groups. Compound No. 14 dose formulation was prepared once and used for dosing on days 2, 5, and 8.

[0316] Radiation treatment in Studies 1 and 2 was performed using a RadSource RS 2000 X-ray irradiator (Rad Source Technologies). Animals received radiation at 1.046 Gy / min, requiring approximately 9.5 minutes to achieve a 10 Gy dose. Animals were anesthetized with isoflurane and checked for reflexes before being placed in the irradiation chamber. The radiation beam was manually positioned and focused on the tumor. Radiation was administered by manual positioning in a single 10 Gy dose on either day 0, 2, or 4 of Study 1 and on either day 0, 1, 2, 3, or 4 of Study 2.

[0317] Study 3: A 0.1 mg / mL stock solution of Compound No. 14 was formulated in PBS and administered IV using a dose volume of 10 mL / kg body weight based on the exact animal weight on each day of treatment. The final dose received was 0.25 mg / kg or 1.0 mg / kg. Compound No. 14 was administered on a Q3D schedule of three doses (days 12, 15, and 18) in the single-agent and combination treatment groups. The Compound No. 14 dose formulation was prepared once and used on all three days of administration.

[0318] Anti-mPD-1 antibody (clone RMP1-14) and an isotype control that does not bind to mPD-1 (mIgG2a, clone 2A3) (both from Bio X Cell, 10 Technology Drive, Suite 2B, West Lebanon, NH 03784) were formulated at 1.0 mg / mL in PBS before the first injection on day 12 and administered intraperitoneally (IP) based on exact body weight on each day of treatment at a dose of 10 mg / kg using a dosage volume of 0.01 mL / g. The formulated anti-mPD-1 and isotype control were stored at 4°C until subsequent dosing on days 15 and 18. Anti-mPD-1 or the isotype control was administered simultaneously with Compound #14 or vehicle control on a 3-dose Q3D schedule (days 12, 15, and 18) in the single-agent and combination treatment groups.

[0319] Radiation treatment in Study 3 was performed using focal beam irradiation with volumetric image guidance from a computed tomography scan SARRP (Small Animal Radiation Research Platform) irradiator (Xstrahl Inc., Suwanee, GA). Animals received radiation at 2.42 Gy / min, requiring approximately 3.3 minutes to reach a dose delivery of 8 Gy. Animals received 8 Gy of radiation on days 8, 9, and 10, with the final radiation dose administered 2 days before the start of Compound 14 and / or anti-mPD-1 or relevant control treatment on day 12. During imaging and radiation treatment, animals were anesthetized using 1-2% isoflurane. When radiation treatment was repeated daily, the same treatment plan was applied, adjusting for changes in animal positioning or target shifts over time. Sham-irradiated animals received no radiation but were anesthetized for the same amount of time as irradiated animals to control for the non-irradiated portion of the treatment.

[0320] Study 4: A 5 mg / mL stock solution of Compound No. 14 was formulated in PBS at a final concentration of 0.0667 mg / mL and administered intravenously (IV). The final dose received was 0.25 mg / kg. Compound No. 14 dose volume did not exceed 0.2 mL. Compound No. 14 was administered in single and combination treatment groups on a QW schedule of 3 doses starting on Day 1. Compound No. 14 dose formulation was prepared once and used for dosing on each treatment day.

[0321] Study 5: A 5 mg / mL stock solution of Compound No. 14 was formulated in PBS at a final concentration of 0.0667 mg / mL and administered intravenously (IV). The final dose received was 0.25 mg / kg. Compound No. 14 administered did not exceed 0.2 mL. Compound No. 14 was administered in the single-agent and combination treatment groups on a Q3D schedule of 3 doses starting on Day 1. Compound No. 14 dose formulations were prepared once and used for dosing on each treatment day.

[0322] Studies 4 and 5: Anti-mPD-1 antibody (clone RMP1-14) and an isotype control that does not bind to mPD-1 (mIgG2a, clone 2A3) (both from Bio X Cell, 10 Technology Drive, Suite 2B, West Lebanon, NH03784) were formulated at 2.1 mg / mL in PBS prior to each injection and administered intraperitoneally (IP) at a dose of 10 mg / kg using a dose volume of 0.1 mL / mouse. Anti-mPD-1 or the isotype control was administered simultaneously with Compound #14 or vehicle control on a 3-dose BIN schedule in the single-agent and combination treatment groups.

[0323] Studies 4 and 5: Radiation treatment in Studies 4 and 5 was performed using focal beam irradiation with volumetric image guidance from computed tomography scans on a SmART (Small Animal Image-Guided Radiation Therapy) platform (Precision XRay Inc., North Branford, CT). Animals received radiation at 4.52 Gy / min, requiring approximately 1.8 minutes to achieve a dose delivery of 8 Gy (Study 4) or 2.6 minutes to achieve a dose delivery of 16 Gy (Study 5). Animals were anesthetized using 1-2% isoflurane during imaging and radiation treatment.

[0324] Tumor measurements Tumors were measured three times a week using calipers. Tumor volume was calculated using the following standard equation: V = W 2 × L / 2 (where V = volume, W = width, and L = length for tumors). The mean tumor volume in Study 1 was approximately 60 mm 3 , mean tumor volume in Study 2 was 75 mm 3 , and the mean tumor volume in Study 3 was 110 mm 3 When tumor volume reached 2,000 mm, mice were randomized into eight groups (n=10 / group) in Studies 1 and 2, and nine groups (n=8 / group) in Study 3. These groups were then administered vehicle (PBS), Compound No. 14, radiation, anti-mPD-1 or isotype control, or a combination of these agents as described in Tables 1a, 2a, and 3a. Tumor size and body weight were measured three times weekly for the duration of each study. Mice were euthanized in Studies 1 and 2 when their tumor volume reached more than 10% of body weight, or when individual tumors exceeded the humane endpoint in size (>2 cm), or when animals lost 20% of body weight compared to the start of the study, or 15% of body weight in any 24-hour time frame. Mice were euthanized when tumor volume reached 2,000 mm. 3 Animals were euthanized in Study 3 when the body weight exceeded 100 mg / kg or when they lost more than 20% of their body weight compared to the start of the study.

[0325] Statistical analysis of comparison of different treatments in a mouse syngeneic tumor model The following statistical analysis methods were used in Studies 1, 2, 4, and 5.

[0326] Growth rate inhibition: As described in more detail below, differences in tumor growth trends over time between treatment groups were assessed by fitting each animal's data to a simple exponential growth model and comparing the mean growth rates of the two groups. Differences in growth rate were summarized by the GRI, which is the reduction in growth rate experienced by a treatment group compared to the growth rate of the reference group, expressed as a percentage of the vehicle growth rate.

[0327]

number

[0328] μ T and μ C μ are the mean tumor growth rates of the treatment and reference groups, respectively. V is the mean tumor growth rate of the vehicle group, which in most cases is the same as the reference group.

[0329] A positive GRI indicates that the tumors in the treatment group grow at a reduced rate compared to the reference group. A GRI of more than 100% is interpreted as tumor regression when the vehicle group is identical to the reference group. A negative GRI value means that the tumors in the treatment group grow faster than the tumors in the reference group. Statistical significance was determined using unpaired t-test. A statistically significant P value suggests that the time trends of the two treatment groups are different.

[0330] Calculation of tumor growth rate: Because low tumor volumes can cause problems in data analysis, 3 All measurements below 0 (including 0 values) were excluded from the analysis. After this exclusion step, tumor volume was assumed to follow an exponential growth model. More specifically, for a given animal and treatment group: log 10 (V i )=a+b×t i +ε i In the formula, V iis the tumor volume at the i-th time point, where a is the initial logarithmic volume, b is the tumor growth rate, and t i is the measurement time (number of days). i is the residual error term, which is assumed to be uncorrelated and removed from a normal distribution.

[0331] This model was fitted separately to each animal within each treatment group. If an animal was sacrificed or died prematurely but had at least two unique time points (including baseline), data up to that time point were used to estimate growth rate. If an animal had measurements at fewer than two time points, it was automatically excluded from the analysis.

[0332] In rare cases, the estimated growth rate of one or more animals may differ significantly from other animals in the same group. To ensure robustness of the analysis, intervals were defined with a width 30 times the median absolute deviation of the estimated growth rate for a given group. The intervals were centered on the median growth rate of the group. If the growth rate of any animal fell outside this interval, the growth rate was replaced by the value at the boundary of the interval.

[0333] Combination Analysis: Combination analysis was performed to determine whether there was a benefit from combining drug treatments. This analysis was also based on estimated tumor growth rates. The measure of synergy was defined as follows:

[0334]

number

[0335] where μ AB , μ A , μ B , and μ 対照 are the average growth rates of the combination group, drug A group, drug B group, and control group, respectively. Vis the mean tumor growth rate of the vehicle group, which is in most cases the same as the control group. The standard error of the synergy score was calculated as the square root of the sum of the standard errors across the four groups. The degrees of freedom were estimated using the Welch-Satterthwaite equation. A hypothesis test was performed to determine whether the synergy score was different from 0. The P value was calculated by dividing the synergy score by its standard error and tested against a t-distribution (two-tailed) with the above calculated degrees of freedom. A P value of less than 0.05 is statistically significant.

[0336] Combination results can be interpreted as follows: A statistically significant negative synergy score indicates a synergistic combination; A statistically significant positive synergy score indicates a sub-additive combination when the combination outperforms (i.e., has a lower growth rate) the best-performing single agent; A statistically significant positive synergy score indicates an antagonistic combination when the combination performs worse than the best-performing single agent; Scores that are not statistically significant should be considered additive.

[0337] The following statistical analysis methods were used in Study 3.

[0338] Pairwise comparisons with the vehicle group: All tumor volumes were multiplied by a value of 5 before logarithmic transformation. After transformation, linear interpolation was used to determine the tumor volume of each mouse within 1000 mm. 3 The time (in days) from randomization for mice to reach a tumor size of 1000 mm was estimated. 3 The event of reaching 1000 mm was considered a "tumor progression" event, and the estimated time was called the time to progression (TTP). 3If the TTP was not reached, the mouse's final day on study was recorded and right-censored. For each treatment pair of interest, a parametric survival model was used to estimate the hazard ratio (HR) between the two treatment arms, using a Weibull distribution for TTP. The HR reflects the proportion of hazards that mice in the two treatment arms experienced a progression event at any time throughout the study. An HR between treatment A and treatment B less than 1 suggests that treatment A is more effective than treatment B. Standard errors (SE) and 95% confidence intervals (CI) were also calculated to account for the uncertainty of the estimated HR. Finally, two types of tests were used to calculate P values ​​to assess the statistical significance of the difference between the two treatments: 1) the Wald test p-value from the Weibull survival model; and 2) the nonparametric log-rank test.

[0339] Effect of combination treatment: The benefit of the combination was also based on TTP. Synergy was assessed from the Weibull model. Synergy HRs (hazard ratios) were interpreted as follows:

[0340]

number

[0341] In the formula, λ A|Ctrl and λ B|Ctrl are the hazard ratios for comparing treatments A and B with the vehicle control group, respectively, and λ AB|Ctrl is the hazard ratio comparing the combination with the vehicle group. 相乗効果 If the estimated value of λ is significantly less than 1, it means that there is a synergistic effect between the two treatment groups. In practice, we use three independently estimated hazard ratios to calculate λ. 相乗効果 Instead of calculating λ, we fit a Weibull regression model for all four treatment groups with terms for treatments A and B and their interaction. Thus, the interaction term is calculated as log(λ 相乗効果 ) can be interpreted as follows: 相乗効果is calculated by exponentiating the estimated interaction term, and its p-value is obtained by testing whether the interaction term is significantly different from zero on a logarithmic scale.

[0342] result Study 1: Tumor growth rate inhibition for treatment groups from Study 1 is shown in Table 1a. The effect of the combination over the period up to day 19 is shown in Table 1b. Tumor growth curves for each group are shown in Figure 1.

[0343] All treatment groups demonstrated statistically significant GRIs on Day 19 compared with the vehicle group. Synergy analysis performed using data through Day 19 demonstrated an additive benefit of Compound #14 plus radiation (10 Gy on Day 0, 2, or 4) across all three schedules when compared with single-agent Compound #14 and the matched radiation-only group. While no synergistic benefit was detected during this 19-day period, more complete regressions were achieved in the combination treatment groups compared with the radiation-only or single-agent Compound #14 groups for the remainder of the 72-day study. When Compound #14 was administered in combination with radiation on Days 0, 2, and 4, one, one, and two complete responders (CRs) were detected, respectively. In contrast, there were zero, zero, and one CR in the radiation-only group (those receiving radiation on Days 0, 2, or 4, respectively), and zero CRs in the single-agent Compound #14 group.

[0344] [Table 3]

[0345] [Table 4]

[0346] Study 2: Tumor growth rate inhibition for treatment groups from Study 2 is shown in Table 2a. Combination effects over the period up to day 21 are shown in Table 2b. Tumor growth curves for each group are shown in Figure 2.

[0347] All treatment groups demonstrated statistically significant GRIs on Day 21 compared with the vehicle group. Combination analyses performed using data up to Day 21 of the study showed that the combination of Compound No. 14 plus radiation (10 Gy on Day 2) was synergistic when compared with the single-agent Compound No. 14 and radiation-only (10 Gy on Day 2) groups. Combining Compound No. 14 with radiation on other schedules (10 Gy on Days 0, 1, 3, or 4) provided additive benefits when compared with the single-agent Compound No. 14 and radiation-only arms. For the remainder of the 60-day study, more CRs were achieved in three of the combination treatment groups compared with the radiation-only or single-agent Compound No. 14 groups. When Compound No. 14 was administered in combination with radiation on Days 2, 3, and 4, two, four, and two CRs were detected, respectively (Table 2a). In contrast, there were no CRs in the radiation alone group, the single-agent Compound No. 14 group, or the combination group where radiation was administered on day 0 or day 1.

[0348] [Table 5]

[0349] [Table 6]

[0350] Study 3: The progression-free time analysis of treatment groups from Study 3 is shown in Table 3a. The combined analysis results are shown in Table 3b. Kaplan-Meier survival curves for each group are shown in Figure 3a. Tumor growth curves are shown in Figure 3b.

[0351] All treatment groups, including Compound No. 14 (0.25 mg / kg or 1 mg / kg) or 8 Gy x 3 radiation, showed a significant reduction in TTP (tumor volume > 1000 mm) compared to the control group. 3The study showed a statistically significant increase in TTP (time to reach 100% TTP). Anti-mPD1 as a single agent did not significantly increase TTP compared to control. A statistically significant synergy was demonstrated between Compound #14 (1 mg / kg) and 8 Gy x 3 radiation with anti-mPD1 (Group 8) or isotype control (Group 6). Significant synergistic activity was also demonstrated between Compound #14 (0.25 mg / kg) and 8 Gy x 3 radiation and anti-mPD1 (Group 9). In contrast, in this experiment, the combination of anti-mPD1 and 8 Gy x 3 radiation was not synergistic (Group 7).

[0352] The survival curves for the study in Figure 3a represent the number of mice remaining in the study in each group on a given study day. 3 Mice were removed from the study when their body weight exceeded 100 mg / kg or when the animals lost more than 20% of their body weight compared to the start of the study. The survival graph shows that five mice in Group 6 [Compound No. 14 (1 mg / kg) + isotype control + 8 Gy x 3 radiation] and five mice in Group 8 [Compound No. 14 (1 mg / kg) + anti-mPD1 + 8 Gy x 3 radiation] remained in the study as tumor-free survivors at the end of the study (Day 108). In contrast, no mice in the relevant comparison groups (Gr2, 5, 7) remained in the study beyond Day 53, indicating a sustained benefit of these combinations.

[0353] [Table 7]

[0354] [Table 8]

[0355] Study 4: Tumor growth rate inhibition for treatment groups from Study 4 is shown in Table 4a. Combination effects for the period up to day 11 are shown in Table 4b. Kaplan-Meier survival curves are shown in Figure 4a, and tumor growth curves for each group are shown in Figure 4b.

[0356] Antitumor activity (compared to vehicle) was greatest in animals treated with the triple combination of Compound #14 + radiation + anti-mPD-1 treatment (GRI 101%, p<0.001). The combination of Compound #14 and radiation also demonstrated significant antitumor activity compared to vehicle, but to a lesser extent than the triple combination (GRI 88%, p<0.001). Radiation therapy alone also demonstrated moderate antitumor activity compared to vehicle, but this was weaker than either the double or triple combination groups (63%, p=0.001). In contrast, minimal antitumor activity was observed in animals treated with either Compound #14 or anti-PD-1 treatment alone (GRI 13%, p=0.698, or GRI −2%, p=0.792, respectively). All of these treatments were well tolerated, and no animals were withdrawn from the study due to weight loss greater than 20%.

[0357] [Table 9]

[0358] [Table 10]

[0359] Study 5: Tumor growth rate inhibition for treatment groups from Study 5 is shown in Table 5a. Combination effects through day 10 are shown in Table 5b. Kaplan-Meier survival curves are shown in Figure 5a, and tumor growth curves for each group are shown in Figure 5b.

[0360] Antitumor activity (compared to vehicle) was greatest in animals treated with the combination of Compound #14 and radiation (GRI 67%, p<0.001). Radiation and Compound #14 treatment alone also showed moderate antitumor activity compared to vehicle, but this was weaker than the dual combination group (35%, p=0.009 and GRI 11%, p=0.036, respectively). All of these treatments were well tolerated, with no animals losing more than 20% body weight leading to withdrawal from the study.

[0361] [Table 11]

[0362] [Table 12]

[0363] Example 2: Clinical Study Evaluating Compound No. 14 in Combination with Anti-PD-1 Antibody and Radiation in the Treatment of Patients with Metastatic Solid Tumors An open-label, Phase 1 dose-escalation study will be conducted to evaluate the safety, tolerability, and preliminary antitumor activity of Compound 14 and pembrolizumab following radiation therapy in the treatment of patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous cell carcinoma of the head and neck (SCCHN) who have progressed or are progressing on a checkpoint inhibitor (CPI). Information obtained during this study will be used to estimate the maximum tolerated dose (MTD) and determine the recommended Phase 2 dose (RP2D) of this combination.

[0364] Approximately 46 patients with metastatic NSCLC, TNBC, or SCCHN will be enrolled in the study, achieving a maximum of 39 dose-limiting toxicity (DLT)-evaluable patients. All patients will receive image-guided radiation therapy (IGRT) at 8 Gy x 3 fractions (i.e., 3 fractions of 8 Gy each), followed by intravenous (IV) administration of pembrolizumab and Compound #14.

[0365] Pembrolizumab will be administered at 200 mg IV on day 1 of every 21-day cycle, with a minimum of 40 hours between the last fraction of radiation therapy and the start of IV pembrolizumab. Compound #14 will be administered in a dose-escalation fashion according to a Bayesian optimal interval (BOIN) design, with an initial exploratory dose range of 0.2 to 2.5 mg administered on days 1, 8, and 15 of each 21-day cycle. Patients will receive only Compound #14 with pembrolizumab at dose levels previously deemed safe in the dose-finding Phase 1 study TAK-676-1002.

[0366] Three patients will be enrolled in the initial cohort at a previously specified starting dose level of Compound #14. Subsequent cohorts will enroll two to three patients according to the escalation / tapering guidelines. Pembrolizumab (every 3 weeks) and Compound #14 (weekly) administration will continue until disease progression, intolerance to pembrolizumab or Compound #14 (defined as the occurrence of a treatment-emergent adverse event (TEAE) at least possibly related to pembrolizumab or Compound #14 that warrants dose discontinuation), or withdrawal of consent, whichever occurs first.

[0367] Adverse events (AEs) will be assessed, and clinical laboratories, vital signs, ECGs, and other clinically necessary tests will be obtained to evaluate the safety and tolerability of the investigational drug in combination with radiation. Toxicity will be assessed according to the NCI CTCAE, version 5.0, and the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, U.S. Department of Health and Human Services, National Cancer Institute (June 14, 2010). A DLT will be defined as any treatment-emergent adverse event (TEAE) described in the safety assessment that occurs during cycle 1 and that the investigator considers to be at least possibly related to Compound No. 14 in combination with pembrolizumab and radiation. TEAEs meeting the DLT definition occurring in subsequent cycles will be considered in determining the RP2D for Compound No. 14.

[0368] Radiological evaluation (CT scan and / or magnetic resonance imaging (MRI) if clinically indicated) will be used to assess patients' underlying disease status. Archived formalin-fixed, paraffin-embedded tumor tissue or a minimum number of unstained slides of tumor tissue will be collected from all enrolled patients, where possible, to assess baseline characteristics such as gene mutations, gene signatures, tumor mutation burden, immune cell content, or biomarkers of response or resistance to treatment that may arise from future preclinical or clinical trials. All patients with safely accessible lesions outside the radiation field and fresh tumor biopsies enrolled at dose levels of Compound #14 shown to have pharmacodynamic activity will be required to undergo tumor biopsy according to the schedule of events (SOE).

[0369] Serial blood samples will be collected for circulating biomarkers (peripheral proteins, cytokines, and chemokines, including the IFN-inducible chemokine IP-10), immunophenotyping, mRNA expression, receptor sequencing, and cell-free DNA. Disease response assessment will be performed using RECIST version 1.1 (as determined by the investigator) and will be performed according to the System of Experimental Examination (SOE). Serial blood samples to measure plasma concentrations of Compound #14 and related metabolites to understand the metabolism and excretion mechanism of Compound #14 will be obtained at pre-specified time points as described in the SOE.

[0370] Primary endpoint Primary endpoints for this Phase 1 trial may include the frequency and severity of TEAEs, the number of patients with DLTs, the number / percentage of patients with one or more treatment-emergent serious adverse events (TESAEs), and the number / percentage of patients with one or more TEAEs leading to dose modification and treatment discontinuation.

[0371] Safety endpoints will be assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, and the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (November 2017).

[0372] Secondary endpoints Secondary endpoints of this Phase 1 trial may include overall response rate (ORR) (i.e., confirmed complete response (cCR) + confirmed partial response (cPR)), abscopal response rate (ORR abscopal) (i.e., cCR abscopal + cPR abscopal for tumor lesions outside the radiation field), local response rate (ORR local) (i.e., cCR local + cPR local for tumor lesions inside the radiation field), duration of response (DOR) for all tumor lesions (DOR for tumors inside the radiation field (DOR local) and DOR for tumors outside the radiation field (DOR abscopal)), and time to response (TTR) for all tumor lesions (TTR for tumors inside the radiation field (TTR localized) and TTR for tumors outside the radiation field (TT Rabscopal)).

[0373] Response assessment will be performed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Eur. J. Cancer, 45(2):228-47(2009). Taking into account cases of pseudoprogression, patients will be allowed to continue treatment after the initial assessment of PD, provided that PD is not confirmed by subsequent imaging.

[0374] The trial will be conducted in accordance with good clinical practice standards.

[0375] While certain particular embodiments have been illustrated and described, it is to be understood that changes and modifications can be made in accordance with the skills of those skilled in the art without departing from the technology in its broader aspects as defined in the following claims.

[0376] The present disclosure is not limited with respect to the specific embodiments described in this application. As will be apparent to those skilled in the art, modifications and variations can be made without departing from its spirit and scope. Functionally equivalent methods and compositions within the scope of the present disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing description. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. It is to be understood that the present disclosure is not limited to particular methods, reagents, compounds, compositions, or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0377] All publications, patent applications, issued patents, and other documents mentioned herein are incorporated by reference herein to the same extent as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in the text incorporated by reference are excluded to the extent they conflict with definitions in this disclosure.

Claims

1. A compound having the following structure: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof. A cancer treatment agent in combination with radiation.

2. The therapeutic agent described in claim 1, further combined with a checkpoint inhibitor.

3. The method of claim 2, wherein the checkpoint inhibitor is an anti-PD-1 antibody.

4. The method of claim 3, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, lambrolizumab, pidilizumab, BMS-936559, and AMP-224.

5. The method of claim 2, wherein the checkpoint inhibitor is an anti-PD-L1 antibody.

6. The therapeutic agent of claim 5, wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, durvalumab, avelumab, YW243.55.S70, MEDI-4736, MSB-0010718C, LY3300054, BMS-936559, MPDL3280A, and MDX-1105.

7. The method of claim 2, wherein the checkpoint inhibitor is an anti-CTLA-4 antibody.

8. The method of claim 7, wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab.

9. The method according to any one of claims 1 to 8, wherein the radiation is particle radiation.

10. The method of any one of claims 1 to 9, wherein the radiation is administered by external beam radiation.

11. The method of any one of claims 2 to 10, wherein the compound and the checkpoint inhibitor are administered simultaneously.

12. The method of any one of claims 2 to 10, wherein the compound and the checkpoint inhibitor are administered sequentially in separate pharmaceutical compositions.

13. The method of any one of claims 2 to 12, wherein the radiation, the compound, and the checkpoint inhibitor are administered sequentially.

14. The method of any one of claims 2 to 12, wherein the radiation is administered prior to the compound and the checkpoint inhibitor.

15. The therapeutic agent according to any one of claims 1 to 14, wherein the cancer is melanoma, lung cancer, renal cancer, lymphoma, head and neck cancer, urothelial cancer, prostate cancer, bladder cancer, breast cancer, gastric cancer, colon cancer, leukemia, cervical cancer, microsatellite instability high cancer, hepatocellular carcinoma, or Merkel cell carcinoma.

16. The method according to any one of claims 1 to 14, wherein the cancer is a metastatic solid tumor.

17. 17. The method of any one of claims 2 to 16, wherein the checkpoint inhibitor is administered once every 12 weeks, once every 4 weeks, once every 3 weeks, once every 2 weeks, once a week, twice a week, three times a week, or daily.

18. The method of any one of claims 2 to 17, wherein the checkpoint inhibitor is administered on day 1 or day 2 of a treatment cycle.

19. 20. The method of claim 18, wherein the treatment cycle is 14 days, 21 days, 28 days, or 84 days.

20. The method of any one of claims 1 to 16, wherein the compound is administered on days 1, 8, and 15 of a treatment cycle.

21. 21. The method of claim 20, wherein the treatment cycle is 14 days, 21 days, 28 days, or 84 days.

22. The method of any one of claims 1 to 16, wherein the radiation is administered between day -8 and day -1 of a treatment cycle.

23. 23. The method of claim 22, wherein the treatment cycle is 14 days, 21 days, 28 days, or 84 days.

24. The method of any one of claims 2 to 23, wherein the checkpoint inhibitor is administered in an amount of 200 mg.

25. 24. The method of any one of claims 1 to 23, wherein the compound is administered in an amount of 0.05 mg, 0.1 mg, 0.2 mg, 0.4 mg, 0.8 mg, 1.2 mg, 1.6 mg, 2.0 mg, or 2.5 mg.

26. The method of any one of claims 1 to 23, wherein the radiation is administered in fractional doses of about 5 Gy to about 20 Gy, or about 6 Gy to about 18 Gy, or about 8 Gy to about 16 Gy.

27. ​​A compound having the following structure: 【Chemistry 2】 or a pharma- ceutically acceptable salt thereof. A cancer treatment agent in combination with a checkpoint inhibitor.